According to the National Health and Nutrition Examination Survey, only <1% of American adults not treated with statins had triglyceride levels >1000 mg/dL. [6] There are also ethnic differences in triglyceride levels, with non-Hispanic blacks having lower triglyceride levels than non-Hispanic whites and Mexican Americans. [7] Diabetic ketoacidosis, however, is a common complication amongst type-1 diabetics, with cases amongst type-2 diabetics rising. [8] DKA is associated with an increase in triglyceride levels, observed in approximately 30% to 50% of cases. [9] Most cases have triglyceride levels of <1000 mg/dL. [2,3] In reported cases, patients with triglyceride levels higher than 10,000 mg/dL were younger than 21-years-old and had a history of type-1 DM ( Table 2 ). [4,5]
Title of article | Age | DM status | Triglyceride (mg/dL) |
Severe hypertriglyceridemia: a rare and harmful complication in diabetic ketoacidosis, treated successfully with plasmapheresis (7) | 14 | Type 1 | 14,820 |
Severe hypertriglyceridemia in Diabetic ketoacidosis accompanied by acute pancreatitis: case report (8) | 20 | Type 1 | 15,240 |
Hypertriglyceridemia-induced acute pancreatitis with diabetic ketoacidosis: a rare presentation of type 1 diabetes mellitus (4) | 23 | Type 1 | 1100 |
Triad of diabetic ketoacidosis, hypertriglyceridemia, and acute pancreatitis: severity of acute pancreatitis may correlate with the level of hypertriglyceridemia (9) | 50 | Type 2 | 1226 |
The pathophysiology behind DKA-induced HTG is based on insulin resistance or deficiency. When the body lacks insulin or is resistant to insulin, lipolysis occurs, leading to the release of free fatty acids. [4] The increased uptake of free fatty acids into the liver results in a greater production of VLDL, which is eventually converted to triglycerides. Insulin deficiency impedes the activity of lipoprotein lipase, thus interfering with triglyceride metabolism and VLDL catabolism. [10]
Severe HTG increases a patient's risk of acute pancreatitis. This disease can be devastating, with complications such as septic shock and multiorgan failure. Chronically elevated levels of triglyceride are also associated with a higher risk of atherosclerotic cardiovascular disease. [1] Hence it is vital that severe HTG is promptly managed.
The management of HTG begins with lifestyle modifications. Recommendations include weight loss, dietary changes and avoidance of alcohol. Those with moderate triglyceride levels, between 150 and 885 mg/dL, do not have a significant risk of pancreatitis. Thus, these patients can be started on statins to reduce their risk of atherosclerotic cardiovascular disease. [1] If triglyceride levels are persistently high, pharmacological intervention is warranted, beginning with fibrates, which are shown to lower triglyceride levels up to 70%. [11] Fenofibrate is generally preferred over gemfibrozil due to the increased risk of muscle toxicity when used together with statins. [1] In addition, according to the REDUCE-IT trial, omega-3 agents can further reduce triglyceride levels by 15% to 35%. [12] Rarely, plasmapheresis is required to treat HTG acutely. The American Society of Apheresis’ 2016 guidelines recommend the use of plasmapheresis in HTG-induced pancreatitis (Grade 2C). [13] The mechanism is such that during filtration, the passage of high molecular weight molecules such as triglycerides is prevented. [4] The evidence for this therapy is currently not substantial.
There were limitations to our patient evaluation and management. No genetic studies or additional antibody tests, such as islet antigen 2 or insulin autoantibody measurements were performed, which could have provided diagnostic evidence of type-1 DM and lipid disorders. Additionally, we could not exclude HTG triggering DKA. In vitro studies by Garg et al, [10] have shown that “high concentrations of triglyceride-rich CLDL particles may impair insulin action by inhibiting insulin binding to its receptor.” This could imply that insulin-resistance can occur secondary to hyperlipidemia.
In summary, our case represents a rare occurrence of severe HTG with DKA in an adult patient without a history of type-1 DM. This case encourages routine testing lipid panels in those with uncontrolled DM. Though evidence may be lacking, plasmapheresis was effective for this patient. Hence, this case supports the expanded use of plasmapheresis in patients with similar presentations of severe HTG.
I would like to thank my mentors for helping me finalize this report and to Paige, the medical student who helped me with the literature review.
Conceptualization: Pooja Roy.
Data curation: Pooja Roy.
Investigation: Paige Koetter.
Resources: Pooja Roy.
Supervision: John Cinicola.
Validation: Pooja Roy.
Visualization: Pooja Roy.
Writing – original draft: Pooja Roy.
Writing – review & editing: Pooja Roy, Jessica Cunningham, Saketram Komanduri.
case report; diabetic ketoacidosis; plasmapheresis; severe hypertriglyceridemia
A comprehensive review on the hepatotoxicity of herbs used in the indian....
BMC Endocrine Disorders volume 19 , Article number: 121 ( 2019 ) Cite this article
10k Accesses
2 Citations
2 Altmetric
Metrics details
Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes that requires immediate treatment. Allergic reaction to insulin is rare, especially when using recombinant human insulin. The clinical presentation of insulin allergy can range from minor local symptoms to a severe generalized allergic reaction such as anaphylaxis. A limited number of cases have been reported on the treatment of severe DKA in patients with type 2 diabetes with insulin allergy. Here, we describe a patient with type 2 diabetes with insulin allergy in which severe DKA resolved after the initiation of continuous intravenous (IV) recombinant human insulin infusion.
A 58-year-old man with type 2 diabetes initiated subcutaneous insulin administration (SIA) after failure of oral antidiabetic treatment. Symptoms of an allergic reaction developed, including pruritic wheals appearing within 10 min of injection and lasting over 24 h. Both skin prick and intradermal tests were positive with different types of insulin. Two days before admission, he stopped SIA because of allergic symptoms and then experienced weakness and upper abdominal pain. On admission, he was in severe metabolic acidosis with a pH of 6.984 and bicarbonate of 2.5 mmol/litre. The blood glucose level was 20.79 mmol/litre, BUN 4.01 mmol/litre, creatinine 128 μmol/litre, and urinary ketone 11.44 mmol/litre. Over 24 h, metabolic acidosis was refractory to IV fluids, bicarbonate and potassium replacement, as well as haemodialysis. Ultimately, he received continuous IV recombinant human insulin infusion at a rate of 0.1 units/kg/hour, in combination with haemodiafiltration, and no further allergic reactions were observed. On day 5, ketonaemia and metabolic acidosis completely resolved. He had transitioned from IV insulin infusion to SIA on day 14. He was discharged on day 21 with SIA treatment. Three months later, he had good glycaemic control but still had allergic symptoms at the insulin injection sites.
In this patient, SIA caused an allergic reaction, in contrast to continuous IV insulin infusion for which allergic symptoms did not appear. Continuous IV recombinant human insulin infusion in combination with haemodiafiltration could be an option for the treatment of severe DKA in patients with diabetes with insulin allergy.
Peer Review reports
Diabetic ketoacidosis (DKA) is one of the most serious acute complications of diabetes that mainly occurs in patients with type 1 diabetes, but it is not uncommon in some patients with type 2 diabetes [ 1 , 2 ]. The treatment for DKA includes correction of the fluid and electrolyte abnormalities and the administration of insulin. Moreover, patients with refractory DKA may improve following treatment with continuous venovenous haemodiafiltration (CVVHDF) and appropriate supportive care [ 3 , 4 , 5 ]. Allergic reaction to insulin is rare, especially when using recombinant human insulin, with a frequency of less than 1% in patients with diabetes [ 6 ]. The clinical presentation of insulin allergy can range from minor local symptoms to a severe generalized allergic reaction, specifically anaphylaxis [ 7 , 8 ]. Insulin allergy can be managed safely and successfully by desensitization treatment [ 7 , 9 ]. However, a limited number of cases have been reported on the treatment of severe DKA in patients with type 2 diabetes with insulin allergy. Here, we describe a patient with type 2 diabetes with an insulin allergy in which severe DKA resolved after the initiation of continuous intravenous (IV) recombinant human insulin infusion in combination with haemodiafiltration.
In August 2018, a 58-year-old man [height: 169 cm, body weight: 56 kg, and body mass index (BMI): 19.6 kg/m 2 ] was admitted to our emergency department with upper abdominal pain, hyperglycaemia and metabolic acidosis. He had lived with type 2 diabetes for 16 years and had no history of any allergy, hypertension, hyperlipidaemia or renal diseases. Five months prior to admission, he initiated subcutaneous insulin administration (SIA) with the biphasic insulin analogue aspart after failure of sitagliptin and metformin therapies (HbA1c: 8.07% [65 mmol/mol]). Glycaemic control did not improve (HbA1c: 10.2% [88 mmol/mol]; total daily insulin dose was 20 UI), and aspart administration caused mild allergic symptoms. Aspart was then substituted by biphasic human insulin in which the total daily insulin dose increased up to 37 units. However, 5 months after the initiation of these regimens, he developed a pruritic wheal, especially distinct at the injection site (Fig. 1 a). Pruritic wheals appeared within 10 min of injection and lasted over 24 h. The levels of fasting blood glucose and HbA1c deteriorated to 8.6 mmol/litre and 11.2% (99 mmol/mol), respectively. An allergy to insulin was then suspected. A skin prick test was carried out with different types of insulin [insulin aspart (NovoRapid®), recombinant human insulin (Actrapid® and Insulatard®), insulin glargine (Lantus Solostar®), and insulin lispro (Humalog®, Humalog mix®)] in which the test was positive for all of these types. Two days before admission, he stopped SIA because of an allergic reaction and was treated with anti-allergic drugs.
Allergic reactions to insulin. Before admission, the allergic reaction to insulin was characterized by urticaria with wheals (some of which are confluent) and flares (erythaema) on the abdominal wall surrounding the umbilicus ( a ). Over 3 months after being discharged, the local allergic reaction to insulin presents with an erythaema and swelling at the injection site – the outer side and front of the upper right thigh ( b )
One day later, he experienced weakness and upper abdominal pain. On admission, clinical examination revealed a dehydrated patient with a heart rate (HR) of 130 beats/minute, a temperature of 37 °C and a systolic/diastolic blood pressure (BP) of 150/90 mmHg. He was tachypnoeic and dyspnoeic with a respiratory rate (RR) of 28 breaths/minute. He had hot and dry skin without pruritic wheals, isochoric pupils, and had no focal neurological deficit. He had normal breath sounds and a soft and non-tender abdomen. Electrocardiogram showed sinus tachycardia at a rate of 130 beats/minute. Echocardiography revealed normal chamber size and systolic function, without valvular lesions. Laboratory tests revealed high anion gap metabolic acidosis with an arterial blood pH of 6.984, bicarbonate of 2.5 mmol/litre and a serum anion gap (AG) of 26.4 mmol/litre. The arterial PO 2 and PCO 2 levels were 164.3 mmHg and 10.5 mmHg, respectively. Serum glucose was 20.79 mmol/litre, serum lactate was 1.5 mmol/litre, and urinary ketone was 11.44 mmol/litre. Serum potassium, sodium and chloride levels were 5.7 mmol/litre, 137.4 mmol/litre and 114.2 mmol/litre, respectively. Liver and renal function tests were normal, and there was a slightly elevated white blood cell count of 14.1 × 10 9 /l. He was admitted to our emergency ICU with a diagnosis of severe DKA in a patient with type 2 diabetes with an insulin allergy. Intravenous (IV) fluids, bicarbonate and potassium replacement and intermittent haemodialysis (IHD) were initiated. During the first 12 h, he received an initial 1 litre IV bolus of normal saline (0.9% NaCl) in the first hour, followed by a rate of 250 mL/hour, with 26 mmol of potassium chloride added per litre of normal saline. He also received 500 mL of sodium bicarbonate 1.4% solution over 2 h and then repeated as needed. However, his tachypnoea (35 breaths/minute) and metabolic acidosis persisted (arterial blood pH of 7.192, bicarbonate of 4.0 mmol/litre, PO 2 of 156.1 mmHg, PCO 2 of 10.3 mmHg, AG of 24.69 mmol/litre), prompting the initiation of CVVHDF using the Prismaflex® system (Gambro Lundia AB, Sweden) at the following settings: blood flow, 160 mL/minute; replacement volume, 1200 mL/hour; and dialysate, 1200 mL/hour. After 24 h of fluid resuscitation (6500 mL), he was haemodynamically stable and had 3500 mL of urinary output. However, he developed a decreased level of consciousness, agitation, and fatigue of his respiratory muscles. He was intubated for airway protection and was mechanically ventilated for respiratory support. Furthermore, hypotension (HR and BP were 120 beats/minute and 80/40 mmHg, respectively) occurred after intubation. A bolus of normal saline (1000 mL) was provided, and norepinephrine was administered at a rate of 0.3 μg/kg/minute. Haemodynamic stability was recovered after 1 h, with a HR of 110 beats/minute, BP of 120/60 mmHg, and measured CVP value of 8 cmH 2 O. Arterial blood gases revealed a worsening metabolic acidosis with an arterial blood pH of 7.022, bicarbonate of 2.5 mmol/litre and a serum AG of 25.75 mmol/litre. Renal function declined with a serum creatinine level of 198 μmol/litre. Serum glucose, potassium, sodium and chloride levels were 23.32 mmol/litre, 4.35 mmol/litre, 140.5 mmol/litre and 116.6 mmol/litre, respectively. CVVHDF and IV fluids and potassium replacement were continued. Although haemodynamic and respiratory stabilities were maintained, metabolic acidosis persisted. Further skin prick testing with different types of insulin [insulin aspart (NovoRapid®), recombinant human insulin (Actrapid®, Insulatard®, Mixtard®, Humulin R®, and Humulin N®), and insulin glargine (Lantus®)] only showed positivity to two (aspart, human) of these types. However, the intradermal test with these types was positive (the time of testing as shown in Additional file 1 ). A 40 mg dose of methylprednisolone sodium succinate and 10 mg of diphenhydramine were given in the event of the possible occurrence of a severe allergic reaction, and continuous IV infusion of recombinant human insulin was initiated at a rate of 0.1 units/kg/hour. Approximately 60 min after continuous IV infusion of insulin, he developed hypotension without any signs or symptoms of allergic reactions of the skin and mucosa, and the HR was 115 beats/minute and BP was 80/40 mmHg. Infusion of insulin was temporarily stopped followed by intravenous epinephrine administration at a starting rate of 0.15 μg/kg/minute in addition to an IV bolus of 1000 mL of normal saline. He regained haemodynamic stability after 30 min, including a HR of 110 beats/minute and a BP of 120/70 mmHg, and did not require any additional administration of epinephrine after 5 h. Continuous IV infusion of recombinant human insulin at a rate of 0.1 units/kg/hour continued without any events such as signs or symptoms of allergic reactions and hypotension.
On day 5 of follow-up, ketonaemia, metabolic acidosis (arterial blood pH of 7.465, bicarbonate of 18.4 mmol/litre and AG of 12.73 mmol/litre), and renal dysfunction (serum creatinine of 108 μmol/litre) had almost resolved, and CVVHDF was withdrawn. He did not require vasoconstrictors. Continuous IV infusion of recombinant human insulin continued and was adjusted according to blood glucose levels measured with a portable blood glucose meter. He was extubated on day 7 and transitioned from continuous IV insulin infusion to subcutaneous insulin (combined regular human insulin with insulin glargine) administration on day 14. He was discharged on day 21 with SIA (combined regular human insulin with insulin glargine) in combination with an oral antidiabetic drug (sitagliptin and metformin). Three months later, glycaemic control was gradually restored (HbA1c: 8.3% [67 mmol/mol]; total daily insulin dose was up to 44 UI); he still appeared to have mild allergic symptoms, such as local erythaema and swelling, especially distinct at the injection site of insulin glargine (Fig. 1 b).
DKA is not just the hallmark of absolute insulin deficiency in type 1 diabetes; it is increasingly being seen in people presenting with type 2 diabetes [ 2 ]. This condition is a complex disordered metabolic state characterized by hyperglycaemia, high anion gap metabolic acidosis, and ketonuria [ 10 ]. DKA must be distinguished from other causes of high anion gap metabolic acidosis, including lactic acidosis (which can rarely be associated with metformin), aspirin or acetaminophen toxicity and poisoning with methanol, ethylene glycol, and propylene glycol [ 10 , 11 ]. The clinical and laboratory findings of our patient, however, revealed a typical DKA according to the diagnostic criteria proposed by the American Diabetes Association (ADA) [ 10 ]. DKA is an acute, major, life-threatening complication of diabetes that requires immediate treatment. Although DKA has a low rate of hospital mortality, the short-term risk of death is associated with recurrent DKA admissions in patients with diabetes [ 12 ]. However, this disorder can have significant mortality if misdiagnosed or mistreated, which is almost 100% without insulin therapy [ 13 ].
Over the first 30 h after admission, our patient was managed following the ADA guidelines for the treatment of hyperglycaemic crises in adult patients with diabetes [ 10 ], except for the administration of insulin. During this period of time, he also received IHD and CVVHDF for correcting severe DKA, but it persisted. The correction of metabolic acidosis with bicarbonate administration in the treatment of patients with DKA is controversial [ 14 ]. On rare occasions, IHD may be required to treat metabolic acidosis associated with renal failure. Combined CVVHDF with continuous IV insulin infusion was previously performed to treat successfully patients with refractory DKA [ 3 , 5 ]. It is hypothesised that CVVHDF has a role in removal of plasma growth hormone (GH) and insulin growth factor 1 (IGF-1), similar to the clearance of other medium size molecules such as brain natriuretic peptide and procalcitonin [ 4 ]. In our patient, severe DKA was refractory to IHD, and duration of CVVHDF before initiation of continuous IV recombinant human insulin infusion was too short to draw conclusion dealing with clinical effect of CVVHDF in combination with other appropriate supportive care on the treatment of severe DKA. However, severe DKA in our patient resolved over a few days after starting combined CVVHDF with continuous IV recombinant human insulin infusion.
Immediate reactions to insulin preparations are believed to be immunoglobulin (Ig) E-mediated, type I immunologic reactions to insulin or to an additive [ 15 ]. The insulin-IgE complex binds to IgE receptors on the surface of basophils and mast cells, causing release of inflammatory mediators such as histamine, resulting in the minor local to severe generalized allergic reaction [ 16 ]. The IgE and IgG immunoassays were not available at our hospital; therefore, the patient was not assessed. However, his clinical features and skin tests showed a typical type-I allergic reaction according to the Gell and Coombs classification [ 17 ]. Anaphylaxis is the most severe presentation of an IgE-mediated drug reaction, and the skin and/or mucous membranes are involved in almost all cases [ 18 ]. In our patient, hypotension developed both before and after beginning continuous IV recombinant human insulin infusion, as well as after intubation without any signs or symptoms of allergic reactions of the skin and mucous membranes. However, his haemodynamic stabilities were rapidly obtained after adequate IV fluid replacement, and he did not require any further administration of epinephrine. Three risk factors for post-intubation hypotension were identified by multivariate analysis: decreasing mean arterial pressure pre-intubation, administration of neuromuscular blockers, and intubation complications [ 19 ]. In our patient, hypotension could therefore be attributed to decreasing mean arterial pressure pre-intubation and/or administration of neuromuscular blockers rather than severe allergic reactions.
Insulin allergy can be managed safely and successfully by desensitization treatment with the subcutaneous insulin route [ 7 , 9 , 20 ]. However, insulin tolerability in a severely insulin-allergic patient with diabetes could also be achieved by the use of intravenously injected insulin [ 21 ]. In this patient, treatment attempts of specific immunotherapy with subcutaneous administration of insulin, with continuous subcutaneous injection of insulin lispro, and with oral anti-allergic agents did not prevent frequent life-threatening allergic symptoms, especially after bolus injections with meals. Ultimately, no allergic reactions were observed after the authors applied the required insulin intravenously over a central line at a dose of 100 UI per 500 mL with a portable pump delivering 5–10 mL/hour, adjusted according to self-monitored blood glucose levels [ 21 ]. In our patient, severe DKA was refractory to IV fluid and sodium bicarbonate therapies and IHD. However, DKA resolved within several days after beginning continuous IV recombinant regular human insulin infusion in combination with CVVHDF, and no allergic symptoms were observed as previously described. Moreover, our patient appeared allergic symptoms with subcutaneous administration of insulin after transitioning from continuous IV insulin infusion. This phenomenon was also observed in the patient earlier, of whom the levels of anti-human insulin IgE although returned to normal, as did the levels of anti-human insulin IgG bound/total, without any adverse effect on glucose control, subcutaneous injection of regular insulin still caused immediate allergic reactions [ 21 ]. A previous study found that insulin treatment led to the production of antibodies against insulin [ 22 ]. A literature review had shown that the development of insulin antibodies was initially thought to be due to slight immunogenicity induced by the refining of preparations or the difference in amino acid sequences between species. When genetically engineered preparations of human insulin, however, are used, anti-human insulin IgG subclasses still are frequently detected in patients treated with insulin [ 23 ]. Thus, identical insulin molecules can behave in markedly different ways depending on the route of injection. Additionally, it is possible that the formation of anti-human insulin IgG is caused only by insulin molecules that are in contact with subcutaneous tissue [ 21 ]. These were assumed that some modification of insulin, such as aggregation, leads to the immunologic reactions [ 21 , 24 , 25 ].
In our patient, SIA caused an allergic reaction, in contrast to continuous IV insulin infusion, for which allergic symptoms did not appear. We believe that the presentation and progression of our patient indicated that continuous IV recombinant human insulin infusion in combination with haemodiafiltration could be an option for the treatment of severe DKA in patients with diabetes with insulin allergy.
Not applicable.
American Diabetes Association
Blood pressure
Blood urea nitrogen
Central venous pressure
Continuous venovenous haemodiafiltration
Intensive care unit
Immunoglobulin
Intermittent hemodialysis
Intravenous
Partial pressure of carbon dioxide
Partial pressure of oxygen
Respiratory rate
Subcutaneous insulin administration
Welch BJ, Zib I. Case study: diabetic ketoacidosis in type 2 diabetes: “look under the sheets”. Clin Diab. 2004;22(4):198–200.
Article Google Scholar
Misra S, Oliver N, Dornhorst A. Diabetic ketoacidosis: not always due to type 1 diabetes. Bmj. 2013;346:f3501.
Article CAS Google Scholar
Lee SH, Kim BG, Cho AY, Kim SS, Shin HS, Kim JG, et al. A case of diabetic ketoacidosis with refractory metabolic acidosis successfully treated with continuous Hemodiafiltration. J Korean Soc Emerg Med. 2015;26(5):480–2.
Google Scholar
Mewawalla P, Jaiswal G, Moustakakis M, Sankaranarayanan N, Dasanu CA. Refractory DKA as first presentation of acromegaly and a potential role for continuous venovenous hemofiltration in its successful management. Conn Med. 2011;75(7):405–7.
PubMed Google Scholar
Kawata H, Inui D, Ohto J, Miki T, Suzue A, Fukuta Y, et al. The use of continuous hemodiafiltration in a patient with diabetic ketoacidosis. J Anesth. 2006;20(2):129–31.
Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16(Suppl 3):155–65.
Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. Allergy. 2008;63(2):148–55.
Hanauer L, Batson JM. Anaphylactic shock following insulin injection: case report and review of the literature. Diabetes. 1961;10(2):105–9.
Fujikawa T, Imbe H, Date M, Go Y, Kitaoka H. Severe insulin allergy successfully treated with continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 2012;97(2):e31–3.
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–43.
Funes S, de Morais HA. A quick reference on high anion gap metabolic acidosis. Vet Clin North Am Small Anim Pract. 2017;47(2):205–7.
Gibb FW, Teoh WL, Graham J, Lockman KA. Risk of death following admission to a UK hospital with diabetic ketoacidosis. Diabetologia. 2016;59(10):2082–7.
Kitabchi AE, Wall BM. Diabetic ketoacidosis. Med Clin North Am. 1995;79(1):9–37.
Kamel KS, Halperin ML. Acid-base problems in diabetic ketoacidosis. N Engl J Med. 2015;372(6):546–54.
Velcovsky HG, Federlin KF. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care. 1982;5(Suppl 2):126–8.
Castera V, Dutour-Meyer A, Koeppel M, Petitjean C, Darmon P. Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab. 2005;31(4 Pt 1):391–400.
Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachman PJ, editors. editors Clinical aspects of immunology. 3rd ed. Oxford: Blackwell Scientific; 1975. p. 761–81.
Campbell RL, Hagan JB, Manivannan V, Decker WW, Kanthala AR, Bellolio MF, et al. Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol. 2012;129(3):748–52.
Smischney NJ, Demirci O, Diedrich DA, Barbara DW, Sandefur BJ, Trivedi S, et al. Incidence of and risk factors for post-intubation hypotension in the critically ill. Med Sci Monit. 2016;22:346–55.
Pföhler C, Müller CSL, Hasselmann DO, Tilgen W. Successful desensitization with human insulin in a patient with an insulin allergy and hypersensitivity to protamine: a case report. J Med Case Rep. 2008;2(1):283.
Asai M, Yoshida M, Miura Y. Immunologic tolerance to intravenously injected insulin. N Engl J Med. 2006;354(3):307–9.
Berson SA, Yalow RS, Bauman A, Rothschild MA, Newerly K. Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest. 1956;35(2):170–90.
Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev. 2007;28(6):625–52.
Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci. 1997;86(5):517–25.
Maislos M, Mead PM, Gaynor DH, Robbins DC. The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin. J Clin Invest. 1986;77(3):717–23.
Download references
We thank the patient, his family and the medical staff who cared for him. We thank Associate Professor Bryan Francis McNally, MD, MPH, from the Department of Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, USA for his support with our manuscript.
This case report received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Authors and affiliations.
Department of Emergency and Critical Care Medicine, Hanoi Medical University, 01 Ton That Tung street, Kim Lien ward, Dong Da district, Hanoi, Vietnam
Anh Dat Nguyen, Chinh Quoc Luong, Chi Van Nguyen, Tuan Anh Nguyen, Quan Huu Nguyen, Ton Duy Mai, Thong Huu Tran, Phuong Viet Dao, Dat Tuan Nguyen & Son Ngoc Do
Emergency Department, Bach Mai Hospital, 78 Giai Phong road, Phuong Mai ward, Dong Da district, Hanoi, Vietnam
Allerology and Clinical Immunology Center, Bach Mai Hospital, 78 Giai Phong road, Phuong Mai ward, Dong Da district, Hanoi, Vietnam
Hieu Chi Chu, Dinh Van Nguyen & Nguyet Nhu Nguyen
Department of Allergy and Clinical Immunology, Hanoi Medical University, 01 Ton That Tung street, Kim Lien ward, Dong Da district, Hanoi, Vietnam
Endocrinology and Diabetes Department, Bach Mai Hospital, 78 Giai Phong road, Phuong Mai ward, Dong Da district, Hanoi, Vietnam
Van Khoa Dieu Nguyen & Bay Quang Nguyen
Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam, 01 Ton That Tung street, Kim Lien ward, Dong Da district, Hanoi, Vietnam
You can also search for this author in PubMed Google Scholar
CQL wrote the manuscript, researched the data, and contributed to the discussion. ADN contributed to the discussion and reviewed/edited the manuscript. HCC contributed to the discussion. VKDN contributed to the discussion. CVN contributed to the discussion. TAN contributed to the discussion. QHN contributed to the discussion. TDM contributed to the discussion. DVN contributed to the discussion. BQN researched the data and contributed to the discussion. THT contributed to the discussion. PVD researched the data. DTN researched the data. NNN researched the data. SND contributed to the discussion and reviewed/edited the manuscript. All authors approved the final version of the manuscript. Guarantor: CQL.
Correspondence to Chinh Quoc Luong , Tuan Anh Nguyen or Son Ngoc Do .
Ethics approval and consent to participate, consent for publication.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
The authors declare that they have no competing interests.
Publisher’s note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1..
Timeline table for a case report
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated.
Reprints and permissions
Cite this article.
Nguyen, A.D., Luong, C.Q., Chu, H.C. et al. Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report. BMC Endocr Disord 19 , 121 (2019). https://doi.org/10.1186/s12902-019-0451-7
Download citation
Received : 17 July 2019
Accepted : 28 October 2019
Published : 11 November 2019
DOI : https://doi.org/10.1186/s12902-019-0451-7
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
ISSN: 1472-6823
Want to create or adapt books like this? Learn more about how Pressbooks supports open publishing practices.
On March 6th, 2019, Maria Fernandez, a 19-year-old female, presented to the Emergency Department with complaints of nausea, vomiting, abdominal pain, and lethargy. She reveals a recent diagnosis of type 1 diabetes but admits to noncompliance with treatment. At the time of admission, Maria’s vital signs were as follows: BP 87/50, HR 118, RR 28, O2 95% on room air, diffuse abdominal pain at a level of 5, on a verbal numeric 1-10 scale, with non-radiating pain beginning that morning. She was A&O x3, oriented to self, place, and situation, but sluggish. Upon assessment it is revealed that she is experiencing blurry vision, Kussmaul respirations, dry, flushed skin, poor skin turgor, weakness, and a fruity breath smell. Labs were drawn. During the first hour of admission, Maria requested water four times and urinated three times.
Code status: Full code
Medical hx : Type 1 Diabetes
Insurance : None
Allergies : NKA
Significant Lab Values
Diagnosis: Diabetes Ketoacidosis
Maria Fernandez was then transferred to the ICU unit for close observation, maintenance of IV insulin drip, cardiac monitoring, fluid resuscitation, and correction for metabolic acidosis.
Upon discharge, Maria was reeducated on Type 1 Diabetes Mellitus through the use of preferred learning materials.
Henry, N.J., McMichael, M., Johnson, J., DiStasi, A., Ball, B.S., Holman, H.C., Elkins, C.B., Janowski, M.J., Hertel, R.A., Barlow, M.S., Leehy, P., & Lemon, T. (2016). RN adult medical surgical nursing: Review module (10 th ed.). Leawood, KS: Assessment Technologies Institute.
Wolters Kluwer. (2018). Lippincott Nursing Advisor (Version 4.1.0) [Mobile application software]. Retrieved from http://itunes.apple.com
Nursing Case Studies by and for Student Nurses Copyright © by jaimehannans is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License , except where otherwise noted.
Website maintenance is scheduled for Saturday, September 7, and Sunday, September 8. Short disruptions may occur during these days.
DYANNE P. WESTERBERG, DO
This is a corrected version of the article that appeared in print.
Am Fam Physician. 2013;87(5):337-346
Patient Information: A handout on this topic is available at https://familydoctor.org/familydoctor/en/diseases-conditions/diabetic-ketoacidosis.html .
Author disclosure: No relevant financial affiliations.
Diabetic ketoacidosis is characterized by a serum glucose level greater than 250 mg per dL, a pH less than 7.3, a serum bicarbonate level less than 18 mEq per L, an elevated serum ketone level, and dehydration. Insulin deficiency is the main precipitating factor. Diabetic ketoacidosis can occur in persons of all ages, with 14 percent of cases occurring in persons older than 70 years, 23 percent in persons 51 to 70 years of age, 27 percent in persons 30 to 50 years of age, and 36 percent in persons younger than 30 years. The case fatality rate is 1 to 5 percent. About one-third of all cases are in persons without a history of diabetes mellitus. Common symptoms include polyuria with polydipsia (98 percent), weight loss (81 percent), fatigue (62 percent), dyspnea (57 percent), vomiting (46 percent), preceding febrile illness (40 percent), abdominal pain (32 percent), and polyphagia (23 percent). Measurement of A1C, blood urea nitrogen, creatinine, serum glucose, electrolytes, pH, and serum ketones; complete blood count; urinalysis; electrocardiography; and calculation of anion gap and osmolar gap can differentiate diabetic ketoacidosis from hyperosmolar hyperglycemic state, gastroenteritis, starvation ketosis, and other metabolic syndromes, and can assist in diagnosing comorbid conditions. Appropriate treatment includes administering intravenous fluids and insulin, and monitoring glucose and electrolyte levels. Cerebral edema is a rare but severe complication that occurs predominantly in children. Physicians should recognize the signs of diabetic ketoacidosis for prompt diagnosis, and identify early symptoms to prevent it. Patient education should include information on how to adjust insulin during times of illness and how to monitor glucose and ketone levels, as well as information on the importance of medication compliance.
Diabetic ketoacidosis (DKA) continues to have high rates of morbidity and mortality despite advances in the treatment of diabetes mellitus. In a study of 4,807 episodes of DKA, 14 percent occurred in persons older than 70 years, 23 percent in persons 51 to 70 years of age, 27 percent in persons 30 to 50 years of age, and 36 percent in persons younger than 30 years. 1 In a second study of 28,770 persons younger than 20 years (mean age of 14 years) with diabetes, 94 percent had no episodes of DKA, 5 percent had one episode, and 1 percent had at least two episodes. 2 Additionally, DKA occurred more often in females, in persons with a migration background, and in persons 11 to 15 years of age. 2 DKA has a case fatality rate of 1 to 5 percent. 3 , 4 Although the highest rate of mortality is in older adults and persons with comorbid conditions, DKA is the leading cause of death in persons younger than 24 years with diabetes, most often because of cerebral edema. 1 , 4
Although persons with DKA typically have a history of diabetes, 27 to 37 percent have newly diagnosed diabetes. 5 , 6 This is especially true in young children. Most persons with DKA have type 1 diabetes. There is also a subgroup of persons with type 2 diabetes who have ketosis-prone diabetes; this subgroup represents 20 to 50 percent of persons with DKA. 7 Persons with ketosis-prone diabetes have impaired insulin secretion; however, with proper glucose management, beta cell function improves and the clinical course resembles that of type 2 diabetes. 8 These persons are often black or Latino, male, middle-aged, overweight or obese, have a family history of diabetes, and have newly diagnosed diabetes. 9
Venous pH may be measured as an alternative to arterial pH in persons with DKA who are hemodynamically stable and withoutrespiratory failure. | C | |
Serum ketone level should be used in the diagnosis and management of DKA. | C | |
Subcutaneous insulin can be used for treatment of uncomplicated DKA. | C | , |
Bicarbonate therapy has not been shown to improve outcomes in persons with DKA, but is recommended by consensus guidelines for persons with a pH less than 6.9. | C | , |
DKA results from insulin deficiency from new-onset diabetes, insulin noncompliance, prescription or illicit drug use, and increased insulin need because of infection ( Table 1 ) . 4 , 10 – 16 This insulin deficiency stimulates the elevation of the counterregulatory hormones (glucagon, catecholamines, cortisol, and growth hormone). Without the ability to use glucose, the body needs alternative energy sources. Lipase activity increases, causing a breakdown of adipose tissue that yields free fatty acids. These components are converted to acetyl coenzyme A, some of which enter the Krebs cycle for energy production; the remainder are broken down into ketones (acetone, acetoacetate, and β-hydroxybutyrate). Ketones can be used for energy, but accumulate rapidly. Glycogen and proteins are catabolized to form glucose. Together, these factors promote hyperglycemia, which leads to an osmotic diuresis resulting in dehydration, metabolic acidosis, and a hyperosmolar state ( eFigure A ) .
Antipsychotic agents: clozapine (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal) |
Illicit drugs (cocaine ) and alcohol |
Others: corticosteroids, glucagon, interferon, pentamidine, sympathomimetic agents, thiazide diuretics |
Pneumonia, sepsis, urinary tract infection |
Insulin pump failure |
Nonadherence to insulin treatment plans: body image issues, financial problems, psychological factors |
Unrecognized symptoms of new-onset diabetes mellitus |
Acromegaly, arterial thrombosis, cerebrovascular accident, Cushing disease, hemochromatosis, myocardial infarction, pancreatitis, pregnancy, psychological stress, shock/hypovolemia, trauma |
The presentation of DKA varies with severity and comorbid conditions. Polyuria with polydipsia is the most common presenting symptom and was found in 98 percent of persons in one study of childhood type 1 diabetes. Other common symptoms included weight loss (81 percent), fatigue (62 percent), dyspnea (57 percent), vomiting (46 percent), preceding febrile illness (40 percent), abdominal pain (32 percent), and polyphagia (23 percent). 17 Dehydration causes tachycardia, poor skin turgor, dry mucous membranes, and orthostatic hypotension. The metabolic acidosis may lead to compensatory deep (Kussmaul) respirations, whereas increased acetone can be sensed as a fruity smell on the patient's breath. Mental status can vary from somnolence to lethargy and coma. A detailed evaluation may reveal precipitating factors, especially nonadherence to medical regimens and infection, which are common causes of DKA.
Although hyperosmolar hyperglycemic state can be confused with DKA, ketone levels are low or absent in persons with hyperosmolar hyperglycemic state. Other causes of high anion gap metabolic acidosis, such as alcoholic ketoacidosis and lactic acidosis, must be ruled out. Table 2 provides the differential diagnosis of DKA. 14 , 18
Gastroenteritis | |
Hyperosmolar hyperglycemic state | |
Myocardial infarction | |
Pancreatitis | |
Starvation ketosis | |
High anion gap metabolic acidosis: | |
Alcoholic ketoacidosis | |
Ethylene glycol intoxication | |
Lactic acidosis | |
Methanol intoxication | |
Paraldehyde ingestion | |
Rhabdomyolysis | |
Salicylate intoxication | |
Uremia |
The diagnosis of DKA ( Table 3 ) is based on an elevated serum glucose level (greater than 250 mg per dL [13.88 mmol per L]), an elevated serum ketone level, a pH less than 7.3, and a serum bicarbonate level less than 18 mEq per L (18 mmol per L). 4 Although arterial blood gas measurement remains the most widely recommended test for determining pH, measurement of venous blood gas has gained acceptance. One review indicated that venous and arterial pH are clinically interchangeable in persons who are hemodynamically stable and without respiratory failure. 19 Traditionally, the severity of DKA is determined by the arterial pH, bicarbonate level, anion gap, and mental status of the patient ( Table 3 ) . 4 An anion gap greater than 16 mEq per L (16 mmol per L) confirms metabolic acidosis. Although persons with DKA usually have a glucose level greater than 250 mg per dL, a few case reports document DKA in pregnant women who were euglycemic. 20 , 21 Persons with hyperglycemia have pseudohyponatremia, and serum sodium concentration should be corrected. Table 4 provides formulas to calculate the anion gap, serum osmolality, osmolar gap, and serum sodium correction. 16 [ corrected ]
Anion gap | > 10 mEq per L (10 mmol per L) | > 12 mEq per L (12 mmol per L) | > 12 mEq per L (12 mmol per L) | Variable |
Arterial pH | 7.24 to 7.30 | 7.00 to < 7.24 | < 7.00 | > 7.30 |
Effective serum osmolality | Variable | Variable | Variable | > 320 mOsm per kg (320 mmol per kg) |
Mental status | Alert | Alert/drowsy | Stupor/coma | Stupor/coma |
Serum bicarbonate | 15 to 18 mEq per L (15 to 18 mmol per L) | 10 to < 15 mEq per L (10 to < 15 mmol per L) | < 10 mEq per L (10 mmol per L) | > 18 mEq per L (18 mmol per L) |
Serum ketone | Positive | Positive | Positive | Small |
Urine ketone | Positive | Positive | Positive | Small |
Anion gap | Essential for evaluation of acid base disorders | Na– (Cl + HCO ) | 7 to 13 mEq per L (7 to 13 mmol per L) |
Osmolar gap | Difference between measured osmolality and calculated osmolality | Osmolality (measured) – osmolality (calculated) | < 10 mmol per L |
Serum osmolality | Measure of particles in a fluid compartment | 2(Na + K) + (glucose/18) + (blood urea nitrogen/2.8) | 285 to 295 mOsm per kg (285 to 295 mmol per kg) of water |
Serum sodium correction | Hyperglycemia causes pseudohyponatremia | Na + 0.016(glucose – 100) | 135 to 140 mEq per L (135 to 140 mmol per L) |
Urinalysis measures only acetone and acetoacetate, not β-hydroxybutyrate, which is the primary ketone in DKA. In one study, the urine dipstick test was negative for ketones in six of 18 persons. Ketonemia was defined as a ketone level greater than 0.42 mmol per L. 22 In a second study of point-of-care testing in the emergency department, urine dipstick testing for ketones had a sensitivity of 98 percent, specificity of 35 percent, and a positive predictive value of 15 percent. Serum testing for β-hydroxybutyrate had a sensitivity of 98 percent, a specificity of 79 percent, and a positive predictive value of 34 percent (using a cutoff of greater than 1.5 mmol per L), allowing for more accurate diagnosis of DKA. 23 The American Diabetes Association has revised its position on ketone analysis in favor of serum testing, and has concluded that capillary measurement is equivalent to venous measurement. 4 , 22 , 24
Further initial laboratory studies should include measurement of electrolytes, phosphate, blood urea nitrogen, and creatinine; urinalysis; complete blood count with differential; and electrocardiography ( Table 5 ) . 16 Potassium level is normal or low in persons with DKA, despite renal losses caused by the acidic environment. An initial potassium level less than 3.3 mEq per L (3.3 mmol per L) indicates profound hypokalemia. Amylase and lipase levels may be increased in persons with DKA, even in those without associated pancreatitis; however, 10 to 15 percent of persons with DKA do have concomitant pancreatitis. 18 , 25
A1C | To determine level of glycemic control in persons with diabetes mellitus |
Anion gap (electrolytes) | Usually greater than 15 mEq per L (15 mmol per L) |
Arterial blood gas measurement | Below 7.3 |
Arterial blood gas measurement is the most widely recommended test for determining pH, but measurement of venous blood gas has gained acceptance | |
Blood urea nitrogen, creatinine levels | Usually elevated because of dehydration and decreased renal perfusion |
Complete blood count (with differential) | May be elevated in persons with DKA, but without pancreatitis |
Diagnosis of pancreatitis should be based on clinical judgment and imaging | |
Electrocardiography | Assesses effect of potassium status; rules out ischemia or myocardial infarction |
Serum bicarbonate level | Less than 18 mEq per L (18 mmol per L) |
Serum glucose level | Point-of-care testing at presentation |
Usually greater than 250 mg per dL (13.88 mmol per L) | |
Pregnant women may have low to normal levels | |
Serum ketone level | Point-of-care testing at presentation |
Usually 7 to 10 mmol per L, or greater than 1:2 dilution | |
Serum magnesium level | Can be low or normal because of osmotic diuresis |
Serum osmolality | Greater than 320 mOsm per kg (320 mmol per kg) |
Serum phosphate level | May be normal or elevated initially, but usually decreases with treatment |
Serum potassium level | May be low, normal, or elevated |
Serum sodium level | Usually low |
Patient may have pseudohyponatremia that should be corrected | |
Urinalysis | Confirms the presence of glucose and ketones, and will help assess for presence of a urinary tract infection |
Chest radiography | Perform if pneumonia or pulmonary disorder is suspected |
Serum amylase/lipase level | May be elevated in persons with DKA, even in those without associated pancreatitis |
Diagnosis of pancreatitis should be based on clinical judgment and imaging | |
Serum creatine kinase and troponin levels | May be elevated in persons with DKA in the absence of myocardial infarction |
Diagnosis of myocardial infarction should be based on clinical judgment and imaging | |
Serum hepatic transaminase levels | Mild increases can occur, especially in persons with fatty liver disease |
Urine and blood cultures | Perform if infection is suspected |
Leukocytosis can occur even in the absence of infection; bandemia more accurately predicts infection. One study showed that an elevated band count in persons with DKA had a sensitivity for predicting infection of 100 percent (19 out of 19 cases) and a specificity of 80 percent. 26 Chest radiography and urine and blood cultures should be added for further evaluation of infection. An elevated hemoglobin level caused by dehydration may also exist. Elevated hepatic transaminase levels may occur, especially in persons with fatty liver disease. 27 Mild increases in creatine kinase and troponin levels may occur in the absence of myocardial damage; one study demonstrated that increased troponin levels occurred in 26 out of 96 persons with DKA without a coronary event. 28 Finally, the A1C level indicates the degree of glycemic control in persons known to have diabetes.
Figure 1 4 , 29 provides the treatment approach for DKA in adults, and Figure 2 24 , 30 provides the treatment approach for DKA in persons younger than 20 years. Both approaches are recommended by the American Diabetes Association. Specific issues for the adult patient are discussed in more detail below. For persons younger than 20 years, insulin should be administered gradually, and fluid and electrolyte replacement should be done cautiously because of limited data and concern for precipitating cerebral edema.
After determining the level of dehydration, intravenous fluid replacement should be started. In most persons, saline 0.9% is started at 15 to 20 mL per kg per hour, or 1 L per hour initially. Fluid status, cardiac status, urine output, blood pressure, and electrolyte level should be monitored. As the patient stabilizes, fluids can be lowered to 4 to 14 mL per kg per hour, or 250 to 500 mL per hour. Once the corrected sodium concentration is normal or high (greater than 135 mEq per L [135 mmol per L]), the solution can be changed to saline 0.45%. Dextrose is added when the glucose level decreases to 200 mg per dL (11.10 mmol per L). 4
To further correct hyperglycemia, insulin should be added to intravenous fluids one to two hours after fluids are initiated. An initial bolus of 0.1 units per kg should be given with an infusion of 0.1 units per kg per hour. 4 Some believe this bolus is unnecessary as long as an adequate infusion of insulin is maintained. 31 An infusion of 0.14 units per kg per hour is recommended in the absence of a bolus. Glucose level should decrease by about 50 to 70 mg per dL (2.77 to 3.89 mmol per L) per hour, and the insulin infusion should be adjusted to achieve this goal. 4 Once the glucose level decreases to 200 mg per dL, the insulin infusion rate should be decreased to 0.05 to 0.1 units per kg per hour, and dextrose should be added to the intravenous fluids to maintain a glucose level between 150 and 200 mg per dL (8.32 and 11.10 mmol per L). 4 Subcutaneous insulin is an effective alternative to intravenous insulin in persons with uncomplicated DKA. 29 In one prospective randomized trial of 45 persons, 15 received insulin aspart (Novolog) hourly, 15 received insulin aspart every two hours, and 15 received standard intravenous infusion of regular insulin. Physiologic and clinical outcomes were identical in all three groups. 32 A meta-analysis supports subcutaneous administration of rapid-acting insulin analogues, such as lispro (Humalog), every hour (bolus of 0.3 units per kg, then 0.1 units per kg) or two hours (bolus of 0.3 units per kg, then 0.2 units per kg) as a reasonable alternative to intravenous regular insulin for treating uncomplicated DKA. 29
DKA is resolved when the glucose level is less than 200 mg per dL, the pH is greater than 7.3, and the bicarbonate level is 18 mEq per L or higher. 4
Once these levels are achieved and oral fluids are tolerated, the patient can be started on an insulin regimen that includes an intermediate- or long-acting insulin and a short- or rapid-acting insulin. When intravenous insulin is used, it should remain in place for one to two hours after subcutaneous insulin is initiated. Persons known to have diabetes can be started on their outpatient dose, with adjustments to improve control. Those new to insulin should receive 0.5 to 0.8 mg per kg per day in divided doses. 4
Although potassium is profoundly depleted in persons with DKA, decreased insulin levels, acidosis, and volume depletion cause elevated extracellular concentrations. Potassium levels should be monitored every two to four hours in the early stages of DKA. Hydration alone will cause potassium to drop because of dilution. Improved renal perfusion will increase excretion. Insulin therapy and correction of acidosis will cause cellular uptake of potassium. If the potassium level is in the normal range, replacement can start at 10 to 15 mEq potassium per hour. During treatment of DKA, the goal is to maintain serum potassium levels between 4 and 5 mEq per L (4 and 5 mmol per L). If the potassium level is between 3.3 and 5.2 mEq per L (3.3 and 5.2 mmol per L) and urine output is normal, replacement can start at 20 to 30 mEq potassium per hour. If the potassium level is lower than 3.3 mEq per L, insulin should be held and replacement should be started at 20 to 30 mEq potassium per hour. If the potassium level is greater than 5.2 mEq per L, insulin therapy without potassium replacement should be initiated, and serum potassium levels should be checked every two hours. When the potassium level is between 3.3 and 5.2 mEq per L, potassium replacement should be initiated. 4 Some guidelines recommend potassium replacement with potassium chloride, whereas others recommend combining it with potassium phosphate or potassium acetate. Clinical trials are lacking to determine which is best, although in the face of phosphate depletion, potassium phosphate is used.
Bicarbonate therapy in persons with DKA is somewhat controversial. Proponents believe that severe acidosis will cause cardiac and neurologic complications. However, studies have not demonstrated improved clinical outcomes with bicarbonate therapy, and treatment has been associated with hypokalemia. In one retrospective quasi-experimental study of 39 persons with DKA and a pH between 6.9 and 7.1, there was no difference in outcomes between those who received bicarbonate therapy and those who did not. 33 A second study of 106 adolescents with DKA showed no difference in outcomes in patients treated with and without sodium bicarbonate, but few had a pH below 7 and only one had a pH below 6.9. 34
Current American Diabetes Association guidelines continue to recommend bicarbonate replacement in persons with a pH lower than 6.9 using 100 mEq of sodium bicarbonate in 400 mL of sterile water with 20 mEq of potassium chloride at a rate of 200 mL per hour for two hours. This should be repeated every two hours until the patient's pH is 6.9 or greater. 4
Phosphate levels may be normal to elevated on presentation, but decline with treatment as the phosphate enters the intracellular space. Studies have not shown a benefit from phosphate replacement, and it can be associated with hypocalcemia and hypomagnesemia. However, because phosphate deficiency is linked with muscle fatigue, rhabdomyolysis, hemolysis, respiratory failure, and cardiac arrhythmia, replacement is recommended when the phosphate level falls below 1.0 mg per dL (0.32 mmol per L) or when these complications occur. 4 Persons with anemia or respiratory problems and congestive heart failure may benefit from phosphate. This can be achieved by adding 20 to 30 mEq of potassium phosphate to the intravenous fluid. 4
DKA can cause a drop in magnesium, which can result in paresthesia, tremor, muscle spasm, seizures, and cardiac arrhythmia. It should be replaced if it falls below 1.2 mg per dL or if symptoms of hypomagnesemia develop. 35
Cerebral edema is the most severe complication of DKA. It occurs in 0.5 to 1 percent of all DKA cases, 36 , 37 and carries a mortality rate of 21 to 24 percent. 30 Survivors are at risk of residual neurologic problems. 38 Cerebral edema predominantly occurs in children, although it has been reported in adults. 39 Risk factors include younger age, new-onset diabetes, longer duration of symptoms, lower partial pressure of carbon dioxide, severe acidosis, low initial bicarbonate level, low sodium level, high glucose level at presentation, rapid hydration, and retained fluid in the stomach. 30 , 40 Signs of cerebral edema that require immediate evaluation include headache, persistent vomiting, hypertension, bradycardia, and lethargy and other neurologic changes.
Other complications of DKA include hypokalemia, hypoglycemia, acute renal failure, and shock. Less common problems can include rhabdomyolysis, 41 thrombosis and stroke, 42 pneumomediastinum, 43 prolonged corrected QT interval, 44 pulmonary edema, 45 and memory loss with decreased cognitive function in children. 46
Physicians should recognize signs of diabetes in all age groups, and should educate patients and caregivers on how to recognize them as well ( eTable A ) . In one study, persons with DKA had symptoms of diabetes for 24.5 days before developing DKA. 17 Persons with diabetes and their caregivers should be familiar with adjusting insulin during times of illness. This includes more frequent glucose monitoring; continuing insulin, but at lower doses, during times of decreased food intake; and checking urine ketone levels with a dipstick test if the glucose level is greater than 240 mg per dL (13.32 mmol per L). 47 More accessible home measurement of serum ketones with a commercial glucometer may allow for earlier detection of DKA and decreased hospital visits. 48 Persons with an insulin pump need to know their pump settings, and should maintain a prescription for basal insulin in case of pump failure.
Education for physicians on early recognition of diabetes mellitus symptoms for prompt diagnosis | |
Education for patients and caregivers on diabetes care | |
24-hour hotline for urgent questions | |
Group visits | |
Referral for diabetes education with certified educator or pharmacist | |
Telecommunication | |
Web-based education ( and ) | |
Sick day management | |
Early contact with clinician | |
Insulin reduction rather than elimination | |
Measurement of urine or serum ketone level | |
Backup insulin protocol in case of insulin pump failure | |
Psychological counseling for those who eliminate insulin for body image concerns, and those who have major depression or other psychological illnesses that interfere with proper management | |
Disparities in care | |
Assess reasons for discontinuation of insulin (e.g., access to health care; social, cultural, economic barriers) | |
Referral to community resources | |
Copay reduction for medication |
Nonadherence to medical regimens is often the cause of recurrent DKA. Physicians need to recognize patient barriers to getting care, such as financial, social, psychological, and cultural reasons. Diabetes education with certified educators and pharmacists enhances patient care. 49 , 50 Other prevention techniques include group visits, telecommunication, web-based learning, and copay reduction for diabetes medications; however, evidence for their effectiveness is mixed. 51 – 55
Data Sources: In July 2010, an initially broad search of PubMed, Essential Evidence Plus, and sources such as the Cochrane database and Clinical Evidence was conducted using the key term diabetic ketoacidosis. In the fall of 2010, another search was conducted using additional key terms, such as incidence and prevalence. As information was collected, individual questions were then searched to add finer points to the documentation. The searches were repeated with each draft of the manuscript.
Henriksen OM, Røder ME, Prahl JB, Svendsen OL. Diabetic ketoacidosis in Denmark incidence and mortality estimated from public health registries. Diabetes Res Clin Pract. 2007;76(1):51-56.
Fritsch M, Rosenbauer J, Schober E, Neu A, Placzek K, Holl RW. German Competence Network Diabetes Mellitus and the DPV Initiative. Predictors of diabetic ketoacidosis in children and adolescents with type 1 diabetes. Experience from a large multicentre database. Pediatr Diabetes. 2011;12(4 pt 1):307-312.
Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985–2002. Diabetes Care. 2006;29(9):2018-2022.
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crisis in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343.
Schober E, Rami B, Waldhoer T Austrian Diabetes Incidence Study Group. Diabetic ketoacidosis at diagnosis in Austrian children in 1989–2008: a population-based analysis. Diabetologia. 2010;53(6):1057-1061.
Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med. 1996;101(1):19-24.
Kim MK, Lee SH, Kim JH, et al. Clinical characteristics of Korean patients with new-onset diabetes presenting with diabetic ketoacidosis. Diabetes Res Clin Pract. 2009;85(1):e8-e11.
Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008;29(3):292-302.
Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144(5):350-357.
Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003;59(1):1-6.
Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001;35(12):1556-1558.
Mithat B, Alpaslan T, Bulent C, Cengiz T. Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium. Pharmacopsychiatry. 2005;38(2):105-106.
Nyenwe EA, Loganathan RS, Blum S, et al. Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract. 2007;13(1):22-29.
Trachtenbarg DE. Diabetic ketoacidosis. Am Fam Physician. 2005;71(9):1705-1714.
Yan L. ‘Diabulimia’ a growing problem among diabetic girls. Nephrol News Issues. 2007;21(11):36.
Wilson JF. In clinic. Diabetic ketoacidosis. Ann Intern Med. 2010;152(1) ):ITC1-1-ITC1-15.
Xin Y, Yang M, Chen XJ, Tong YJ, Zhang LH. Clinical features at the onset of childhood type 1 diabetes mellitus in Shenyang, China. J Paediatr Child Health. 2010;46(4):171-175.
Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol. 2000;95(10):2795-2800.
Kelly AM. The case for venous rather than arterial blood gases in diabetic ketoacidosis. Emerg Med Australas. 2006;18(1):64-67.
Chico M, Levine SN, Lewis DF. Normoglycemic diabetic ketoacidosis in pregnancy. J Perinatol. 2008;28(4):310-312.
Guo RX, Yang LZ, Li LX, Zhao XP. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case-control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. J Obstet Gynaecol Res. 2008;34(3):324-330.
Bektas F, Eray O, Sari R, Akbas H. Point of care blood ketone testing of diabetic patients in the emergency department. Endocr Res. 2004;30(3):395-402.
Arora S, Henderson SO, Long T, Menchine M. Diagnostic accuracy of point-of-care testing for diabetic ketoacidosis at emergency department triage: beta-hydroxbutyrate versus the urine dipstick. Diabetes Care. 2011;34(4):852-854.
Kitabchi AE, Umpierrez GE, Murphy MB, et al.; American Diabetes Association. Hyperglycemic crises in diabetes. Diabetes Care. 2004;27(suppl 1):S94-S102.
Yadav D, Nair S, Norkus EP, Pitchumoni CS. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterol. 2000;95(11):3123-3128.
Slovis CM, Mork VG, Slovis RJ, Bain RP. Diabetic ketoacidosis and infection: leukocyte count and differential as early predictors of serious infection. Am J Emerg Med. 1987;5(1):1-5.
Takaike H, Uchigata Y, Iwamoto Y, et al. Nationwide survey to compare the prevalence of transient elevation of liver transaminase during treatment of diabetic ketosis or ketoacidosis in new-onset acute and fulminant type 1 diabetes mellitus. Ann Med. 2008;40(5):395-400.
Al-Mallah M, Zuberi O, Arida M, Kim HE. Positive troponin in diabetic ketoacidosis without evident acute coronary syndrome predicts adverse cardiac events. Clin Cardiol. 2008;31(2):67-71.
Mazer M, Chen E. Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis?. Ann Emerg Med. 2009;53(2):259-263.
Wolfsdorf J, Craig ME, Daneman D, et al. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes. 2009;10(suppl 12):118-133.
Kitabchi AE, Murphy MB, Spencer J, Matteri R, Karas J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis?. Diabetes Care. 2008;31(11):2081-2085.
Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27(8):1873-1878.
Viallon A, Zeni F, Lafond P, et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis?. Crit Care Med. 1999;27(12):2690-2693.
Green SM, Rothrock SG, Ho JD, et al. Failure of adjunctive bicarbonate to improve outcome in severe pediatric diabetic ketoacidosis. Ann Emerg Med. 1998;31(1):41-48.
Chansky M, Haddad G. Acute diabetic emergencies, hypoglycemia, and glycemic control. In: Parrillo JE, Dellinger RP, eds. Critical Care Medicine: Principals of Diagnosis and Management in the Adult . 3rd ed. Philadelphia, Pa.: Mosby Elsevier; 2008:1245–1257.
Lawrence SE, Cummings EA, Gaboury I, Daneman D. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. J Pediatr. 2005;146(5):688-692.
Glaser N. Cerebral edema in children with diabetic ketoacidosis. Curr Diab Rep. 2001;1(1):41-46.
Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child. 2004;89(2):188-194.
Haringhuizen A, Tjan DH, Grool A, van Vugt R, van Zante AR. Fatal cerebral oedema in adult diabetic ketoacidosis. Neth J Med. 2010;68(1):35-37.
Carlotti AP, St George-Hyslop C, Guerguerian AM, Bohn D, Kamel KS, Halperin M. Occult risk factor for the development of cerebral edema in children with diabetic ketoacidosis: possible role for stomach emptying. Pediatr Diabetes. 2009;10(8):523-533.
Casteels K, Beckers D, Wouters C, Van Geet C. Rhabdomyolysis in diabetic ketoacidosis. Pediatr Diabetes. 2003;4(1):29-31.
Carl GF, Hoffman WH, Passmore GG, et al. Diabetic ketoacidosis promotes a prothrombotic state. Endocr Res. 2003;29(1):73-82.
Weathers LS, Brooks WG, DeClue TJ. Spontaneous pneumomediastinum in a patient with diabetic ketoacidosis: a potentially hidden complication. South Med J. 1995;88(4):483-484.
Kuppermann N, Park J, Glatter K, Marcin JP, Glaser NS. Prolonged QT interval corrected for heart rate during diabetic ketoacidosis in children. Arch Pediatr Adolesc Med. 2008;162(6):544-549.
Young MC. Simultaneous acute cerebral and pulmonary edema complicating diabetic ketoacidosis. Diabetes Care. 1995;18(9):1288-1290.
Ghetti S, Lee JK, Sims CE, Demaster DM, Glaser NS. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr. 2010;156(1):109-114.
Weber C, Kocher S, Neeser K, Joshi SR. Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. Curr Med Res Opin. 2009;25(5):1197-1207.
Laffel LM, Wentzell K, Loughlin C, Tovar A, Moltz K, Brink S. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial. Diabet Med. 2006;23(3):278-284.
Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self-management education. Diabetes Care. 2010;33(suppl 1):S89-S96.
Taveira TH, Friedmann PD, Cohen LB, et al. Pharmacist-led group medical appointment model in type 2 diabetes. Diabetes Educ. 2010;36(1):109-117.
Nair KV, Miller K, Park J, Allen RR, Saseen JJ, Biddle V. Prescription co-pay reduction program for diabetic employees. Popul Health Manag. 2010;13(5):235-245.
Riley SB, Marshall ES. Group visits in diabetes care: a systematic review. Diabetes Educ. 2010;36(6):936-944.
Mayes PA, Silvers A, Prendergast JJ. New direction for enhancing quality in diabetes care: utilizing telecommunications and paraprofessional outreach workers backed by an expert medical team. Telemed J E Health. 2010;16(3):358-363.
Hall DL, Drab SR, Campbell RK, Meyer SM, Smith RB. A Web-based interprofessional diabetes education course. Am J Pharm Educ. 2007;71(5):93.
Wiecha JM, Chetty VK, Pollard T, Shaw PF. Web-based versus face-to-face learning of diabetes management: the results of a comparative trial of educational methods. Fam Med. 2006;38(9):647-652.
More in pubmed.
Copyright © 2013 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.
Copyright © 2024 American Academy of Family Physicians. All Rights Reserved.
Play this case online for free with Full Code
Brief narrative description of case.
The patient’s parents brought her in for vomiting, and “tiredness.” The whole family has had the flu for the past week and all three children were home from school with fever, myalgias, diarrhea. She had a negative COVID-19 swab at a community testing site yesterday. Her siblings seem to be feeling better, but she hasn’t improved yet. She is somnolent, ill-appearing, and severely dehydrated. She is in early hypotensive shock with poor perfusion. Intravenous access attempts will be minimally effective (22g only x 1). She is hyperglycemic, and there is difficulty obtaining additional vascular access. She is hypokalemic (DKA plus diarrhea) and acidotic, which should prompt recognition of DKA with complications.
Management will require IV access (IO), appropriate fluid resuscitation, insulin drip, potassium replacement and admission/transfer.
At the end of this simulation, participants should be able to:
Demonstrate early evaluation of a critically ill patient (application).
Consider risks of aggressive fluid administration in the setting of dka such as cerebral edema (evaluation).
Effectively communicate diagnosis and management to caregivers and respond appropriately to their concerns (synthesis), demonstrate teamwork and closed loop communication (application), critical actions.
Updated March 29, 2023
Chief complaint: Vomiting and lethargy Patient age: 8 years old Weight: 30 kg
Team roles may need to be adjusted in order to suit local practices and norms
This simulation case can be run virtually using Google Slides and Zoom from the Virtual Resus Room (Peds DKA) page.
PC1. Emergency Stabilization PC2. Performance of Focused History & Physical Exam PC3. Diagnostic Studies PC4. Differential Diagnoses and Management PC5. Pharmacotherapy PC9. General Approach to Procedures PC14 . Vascular Access PC15. Medical Knowledge ICS1. Patient Centered Communication ICS2. Team Management
ITEM | FINDING |
---|---|
Overall Appearance | An 8-year-old girl is laying on her bed. Her very anxious mother is at her bedside. She is awake and answering questions appropriately but is clearly miserable, clutching her vomit bag and complaining that her stomach hurts. She has tacky mucous membranes. Note: If using a low fidelity mannequin, the team is to refer to the facilitator. If using a high-fidelity mannequin, the team is to refer directly to the mannequin for feedback. |
HPI | The patient is volunteering very little; she is mostly complaining of generalized abdominal pain (although unable to help pinpoint a specific location for the pain) and anxious about vomiting – although she doesn’t while the medical team is bedside. The mother has limited medical knowledge – and is very anxious that her child will need surgery as she had a friend whose child recently needed stomach surgery. The vomiting and nausea are upsetting her tremendously. Mom will voluntarily share history that the entire family had a cold last week, and everyone improved except the patient who seems worse. Any other history needs to be elicited – and mom will respond to the best of her abilities. She is anxious to help.
|
Past Medical/Surgical History | None |
Medications | No chronic daily medications – mom has given her daily ibuprofen and cough syrup for her “flu” over the last few days |
Allergies | None |
Family History | None – If ever specifically asked, mom comments that maternal grandmother has problems with her sugars |
Social History | No pets, no smokers, 2 siblings, and 2 parents at home |
Evaluation to identification of DKA
* Unbolded items may be excluded depending on local practices and norms
ITEM | FINDING |
---|---|
Vital Signs | : 98.5 F, 130, 90/60, 35, : 99% on RA, : 30 kg |
General | Tired appearing, but arousable and alert and oriented x 3. If residents specifically ask, there is a fruity odor to her breath. |
HEENT | Unremarkable except tacky mucous membranes. Eyes are normal and not sunken. |
Neck | Unremarkable – no stiffness |
Lungs | Clear – but if residents ask, there is Kussmaul breathing (deep rapid breathing) – (Some manikins can do this) |
Cardiovascular | Tachycardia only, no muffled heart sounds |
Abdomen | Non-distended, patient complains of overall discomfort but no point tenderness |
Back | No CVA tenderness |
Neurological | Alert and oriented, but very tired. GCS 14, otherwise normal exam |
Skin | Dry with cool extremities, capillary refill is delayed 4 seconds, no edema |
INTERVENTION / TIME POINT | CHANGE IN CASE | ADDITIONAL INFORMATION |
---|---|---|
Placed on monitors | Vitals are displayed on monitors | Failure to do so within 5 minutes will result in rapid deterioration of patient down cerebral edema pathway. |
Team attempts/asks for intravenous line x 2 | Initial attempt results in one 22G peripheral IV | If residents fail to get second access, patient’s mental status will start to deteriorate. |
IV fluid bolus (normal saline 10-20 mL/kg) | Bolus started | Residents will initially order bolus of 20 mL/kg but reduce to 10 mL/kg over first hour after getting blood glucose level. Practice variation exists with management of DKA (fluid quantities and rates, insulin drip dosing). Learners should follow local standards and practices. |
POC glucose obtained | Result will be 392 mg/dL– should prompt residents to immediately consider DKA. An elevated blood glucose level should prompt discussion to either decrease the IVF rate (to 10 ml/kg) vs keep same (* point for discussion in debrief based on new and old studies- still controversial). | If no POC glucose ordered, RN prompt “Do you want any POC tests?” |
Asks for IVF to be adjusted to 10 mL/kg following glucose result | Fluid volume will be adjusted. | Nursing staff can prompt with question, “Do you need me to adjust the fluid rate at all?” Mom will ask why fluid rate was adjusted and resident will mention that there is a potential for risk of cerebral edema. Mom will be content with this answer. If learners do not decrease fluid rate, the patient will still be fine, but can bring up as a point of discussion the different management options and the controversial nature of the subject. |
VBG | ||
POC serum electrolytes (K+) | Potassium level is 3.1 mEq/L | If learners don’t order POC potassium, the lab will result during . |
Urine ketones | Learners are told the urine will be collected with the next void. | |
CBC ordered | Learners are told results will be available in the standard time for site. They may order antibiotics. | |
Insulin ordered (0.05-0.1 U/ kg/hr) | When insulin is ordered, RN should prompt with, “it will take a couple of minutes to come from pharmacy.” If no POC K+ has been ordered, RN verbalizes need to hold insulin until potassium resulted. Should residents fail to check potassium, can consider ECG changes on monitor (torsades de pointes) and prompt that pathway after insulin started. | |
ECG ordered after POC labs checked | ECG #1 provided (sinus tachycardia with signs of hypokalemia) | |
Ondansetron ordered | Medication is given, and this provides patient and mom with a lot of comfort | Consideration of hypokalemia already and potential for prolonged QTc |
If learners do not verbally identify DKA in first 10 minutes | Increase BP from 90/60 to 150/100 and HR will drop to 80 | Cerebral edema will occur if delay in case progression |
Patient intubated | If intubated, patient will deteriorate with HR increasing to 150, BP dropping to 70/50, and new VBG/CBG will be 6.9/25/2 | |
Team member states concern for DKA and summarizes next steps | Proceed to . | If this does not occur by 10 minutes, RN asks, “What do we think is happening?” |
Identification of DKA through start of insulin drip and IV fluids
ITEM | FINDING |
---|---|
Vital Signs | : 98.5 F, : 121, 98/70, 28, : 98% |
Exam Changes |
INTERVENTION / TIME POINT | CHANGE IN CASE | ADDITIONAL INFORMATION |
---|---|---|
Potassium bolus ordered (0.5 mEq/kg over 1 hour) | Infusion | Potassium bolus should be ordered either as a bolus or in the 2-bag system IVF. If not given prior to or in conjunction with starting insulin, torsades should develop. |
Participants formulate a broad differential: 10 minutes after insulin infusion ordered | Insulin arrives from pharmacy and infusion started. Proceed to . | If the participants do not come up with at least 5 life threatening etiologies on their differential, the nurse can say “What else could this be?” Attending can intervene and guide with thoughtful and intentional questions if the participants go off track. |
Initial 10 mL/kg bolus completed | Capillary refill normalizes. No prolonged cap refill. Defer 2nd bolus. Start maintenance IVF + K. | Practice patterns vary here: Insulin infusion started with second NS bolus of 10 mL/kg : Insulin infusion started with 2-bag system containing potassium |
Maintenance fluids ordered | RN or tech obtains an ECG. Participants will be shown ECG immediately after completion. | If no comment about additional IVF, RN may prompt with “That first bolus is done, do you want any more?” Example: 1.5 x mIVF + 0.5 mEq/kg mEq KCl See regarding 2-bag system. |
If no K+ ordered as bolus or in maintenance fluids | K+ levels drop significantly to K 1.5 mEq/L, and torsades will ensue. | Management of torsades with a pulse: |
PICU consult and/or Endocrine Consult | The PICU team agrees to open up a bed but asks the ED to manage for the next hour or two. Proceed to . |
Time 1 hour after arrival through reassessment (physical exam and labs)
ITEM | FINDING |
---|---|
Vital Signs | : 98.2 F, 111, 110/88, 22, : 99% RA |
Exam Changes | The patient remains alert and oriented. She still has not urinated. Her capillary refill is now <3 sec. |
TIME ADVANCE:
Instructors: please state “time has advanced 1 hour since the patient arrived at the ED.”
INTERVENTION / TIME POINT | CHANGE IN CASE | ADDITIONAL INFORMATION |
---|---|---|
Repeat neurological exam | Mental status improving | |
Repeat blood glucose | POC glucose 300 mg/dL | |
If a second NS bolus was ordered | RN prompt “Second bolus completed” | |
Adjust IVF (2-bag method) – Start the 2-bag method based on the POC glucose obtained now at 300 mg/dL | Discuss 2-bag method of management (details of this discussion are outlined in the debriefing points below) Given her body weight of 30 kg – Because the patient’s blood glucose is 300 mg/dL, | NOTE: Practice points differ between various centers. You may use your local centre practice and protocols. |
Repeat VBG/CBG + electrolytes are completed 1 hour post arrival to ED | 17 mm Hg 40 mmHg sat 75% | |
Discussion with mother about DKA, expectations, admission needs, and immediate management plan | Mom will be appropriately anxious and continues to have poor understanding; NOT aggressive or difficult |
Shock is the state where blood flow to tissues/organs flow does not adequately meet the demand. Children are more susceptible to cardiovascular compromise from shock because of both physiologic differences (compared with adults) and their limited reserve.
In general, the evaluation of a critically ill child requires quick assessment of the pediatric triangle (appearance, breathing, color) in conjunction with the primary survey with an emphasis on the clinical status
Primary survey:
Cerebral injury (or cerebral edema) is rare. Its clinically significant incidence is between 0.3-0.9% of episodes in children with DKA. (Many or most others with DKA will have subclinical cerebral edema without neurological signs). It is more common in children with DKA than adults, and those with the most severe DKA are at highest risk for the cerebral complications. It may be present prior to DKA treatment or during it (between 3-12 hours after treatment begins). The cause is not completely understood. Early work thought it may be the rate of fluid administration but this is being challenged with current lines of research.
– “Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis”: June 14, 2018 — N Engl J Med 2018; 378:2275-2287 (DOI: 10.1056/NEJMoa1716816 )
Patients in severe DKA may also need supplemental IV potassium. Since the goal of insulin administration is closure of the anion gap, supplemental dextrose may be needed when the serum glucose level falls below 250.
When adding dextrose for glucose <250 mg/dL, you may use the “2- bag method”.
Two-Bag Method of IV Fluids in Hypoglycemia
IF BLOOD GLUCOSE LEVEL | IV FLUID BAG(S) |
---|---|
mg/dL | 1 bag |
mg/dL | 2 bags |
mg/dL | 2 bags |
mg/dL | 2 bags |
mg/dL | 1 bag |
mg/dL | 1 bag |
mg/dL | 1 bag |
Hypokalemia in the setting of DKA
Hypokalemia on presentation signifies a profound total potassium deficit. Caution with IV insulin and bicarbonate therapy is warranted, because it could further drop the potassium levels. Davis et al. 2016 presented a case of profound hypokalemia associated with DKA (Pediatr Diabetes Feb; 17 (1): 61-65). In this case, the patient’s potassium level was 1.3 mEq/L. 0.3 mEq/kg KCI over 1 hour was initiated and insulin held until potassium level was 2.7 mEq/L.They reported that their institution had a policy which prevented them from giving a more aggressive replenishment of 0.5 mEq/kg over an hour potassium via a peripheral line. They opted to avoid risks associated with central line placements. Additionally, 30 mEq/L potassium acetate and 30 mEq/L potassium phosphate were given at 1.5x maintenance.
PFCCS (Pediatric Fundamental Critical Care Support) recommends a conservative IV potassium replacements regimen:
Evaluation of a critically ill child should include obtaining a history from all possible sources including EMS, old records (if time), and especially caregivers. Paying attention to details such as trauma or recent illness may give hints toward identifying the underlying pathophysiology. A history of polyuria, polydipsia, increased hunger and weight loss may suggest undiagnosed diabetes. Children may present with DKA after a mild illness so a review of systems should also include evaluation for infection symptoms.
Compassionate, understandable communication with caregivers is critical, as they are strong partners in the treatment of their children. This should not impede lifesaving treatment, but if at all possible, a member of the treatment staff should be assigned to help communicate with parents. Failure to provide a communication liaison may result in anxious parents that may obstruct care. When not actively resuscitating (as in this case), the physician should be able to communicate with patients throughout the child’s care. For complicated concepts, like DKA, it is important to ensure the caregivers understand the explanations being given to them.
Teams may use different frameworks to improve team dynamics and communication. Below are a few definitions that may be helpful to discuss, adapted from the AHRQ TeamSTEPPS Pocket Guide .
Download Case 5 supporting files
For the embedded participants playing the role of the patient and mother
You are bringing your daughter to the ED for vomiting and “tiredness.”
Over the past week the whole family has had the “flu,” with intermittent fevers, myalgias and fevers. Her 3 siblings, however, are all feeling better – but she doesn’t seem to be back to herself. Additionally, for the last 2 days she has been complaining of stomach aches with “too many to count” episodes of vomiting (NB/NB). You took her to an urgent care earlier in the day and they told you that some children take longer to recover from illnesses than others. You’re not satisfied with that response.
Emergency medicine residents
This case is specifically aimed at first and second year residents who should have experience in gathering information from patients and families, and standard medical treatments and procedures. They may be less familiar with escalating medical therapies when first measures are not successful.
Mother: Your demeanor is overall anxious and concerned. You are a nervous parent with limited medical acumen. Interrupt the doctors often with questions – but do not be belligerent or aggressive. You are especially concerned about her stomach-ache and really want to know if she will need surgery. If given space, tell the team about your friend’s daughter who has a stomach-ache and then needed surgery, and then ask repeatedly “is this the same thing?” Her nausea is making you very anxious and want it managed quickly. Something is VERY wrong with your child and you know it. You keep giving her Motrin and Robitussin, but it is not making her any better.
Patient: She doesn’t contribute much. She is awake, tired appearing, not moving a lot on the bed, but intermittently rubs her stomach, clutches her vomit bag (if offered one) and talks about feeling like she might throw up. When examined, she cannot specifically tell them where your pain is – “it’s everywhere.” She is alert and oriented if asked. She is also thirsty if asked.
(Please remember not to offer any of this information, but when asked please respond while remaining in character.)
IMPORTANT: Do not offer unsolicited information. Please allow the learners to ask questions. Do not offer information unless they ask you.
Things Mom could say without being asked:
Things you might say triggered by events in the scenario:
EVENT | YOUR POTENTIAL RESPONSE |
---|---|
If residents are not picking up on DKA | You could offer that your daughter wet her bed two nights ago. “She never wets her bed.” |
If the residents continue not picking up on the diagnosis | You can offer the family history of “sugar problems”. |
The learners enter the room to find a patient who is dry, uncomfortable, and tired appearing – she is mildly somnolent but fully arousable. They immediately place the patient on a bedside monitor and recognize that the patient is in early hypovolemic shock. Access needs to be obtained and might be difficult; the residents can place an IO and an IV fluid bolus should be ordered. Initial blood work should also be ordered at this time – including point of care glucose – the result of which should immediately prompt the residents to move down the DKA management pathway.
After completing a physical examination and obtaining an appropriate history, the learners should note that the patient appears to be worsening – her blood pressure has decreased slightly and remains tachycardic. At this point they discuss the risk of cerebral edema with aggressive fluid management. Patient’s perfusion status remains stable and BP is still above 5% for her age range so conservative management should continue. Insulin is ordered and potassium is measured. Potassium returns 3.1 mEq/L, which should prompt the learners to recognize the need to give potassium (either as a bolus or incorporated into maintenance fluid) prior to the initiation of the insulin drip (regardless of whether they additional IVF). Patient remains stable and starts to hemodynamically improve as the second bolus starts.
No signs of cerebral edema are noted on 1 hr neurologic check. She is admitted to ICU, and the endocrine team is consulted, who will follow the patient in the unit. Prior to the end of the case, DKA diagnosis is explained to the patient and her mother, and DKA education is started.
Return to the EM ReSCu Peds curriculum home page
Please complete our brief survey describing your experience.
Learner (scan or click on QR code)
Facilitator (click or scan QR code)
Latest posts by michelle lin, md ( see all ).
Diabetic ketoacidosis
When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.
Diabetic ketoacidosis (DKA) is characterised by a biochemical triad of hyperglycaemia (or a history of diabetes), ketonaemia, and metabolic acidosis, with rapid symptom onset.
Common symptoms and signs include increased thirst, polyuria, weight loss, excessive tiredness, nausea, vomiting, dehydration, abdominal pain, hyperventilation, and reduced consciousness.
Successful treatment includes correction of volume depletion, ketogenesis, hyperglycaemia, electrolyte imbalances, and comorbid precipitating events, with frequent monitoring.
Complications of treatment include hypoglycaemia, hypokalaemia, pulmonary oedema, and acute respiratory distress syndrome.
Cerebral oedema, a rare but potentially rapidly fatal complication, occurs mainly in children. It may be prevented by avoiding overly rapid fluid and electrolyte replacement.
DKA is an acute metabolic complication of diabetes that is potentially fatal and requires prompt medical attention for successful treatment. It is characterised by absolute or relative insulin deficiency and is the most common acute hyperglycaemic complication of type 1 diabetes mellitus. [1] Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2009 Jul;32(7):1335-43. http://care.diabetesjournals.org/content/32/7/1335.full http://www.ncbi.nlm.nih.gov/pubmed/19564476?tool=bestpractice.com [2] Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults. Mar 2023 [internet publication]. https://abcd.care/sites/abcd.care/files/site_uploads/JBDS_Guidelines_Current/JBDS_02_DKA_Guideline_with_QR_code_March_2023.pdf
This topic covers diabetic ketoacidosis in adults. Bear in mind that people aged 16 to 18 years may be managed by either a paediatric team or an adult medical team according to local arrangements. The Joint British Diabetes Societies for Inpatient Care guideline recommends following paediatric guidelines if the patient is being managed by a paediatric team, and following adult guidance if they are being managed by an adult team. [2] Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults. Mar 2023 [internet publication]. https://abcd.care/sites/abcd.care/files/site_uploads/JBDS_Guidelines_Current/JBDS_02_DKA_Guideline_with_QR_code_March_2023.pdf [3] British Society for Paediatric Endocrinology and Diabetes. BSPED interim guideline for the management of children and young people under the age of 18 years with diabetic ketoacidosis. April 2020 [internet publication]. https://www.bsped.org.uk/media/1798/bsped-dka-guideline-2020.pdf
In the UK, the British Society for Paediatric Endocrinology and Diabetes publishes guidance for the management of DKA in children. [3] British Society for Paediatric Endocrinology and Diabetes. BSPED interim guideline for the management of children and young people under the age of 18 years with diabetic ketoacidosis. April 2020 [internet publication]. https://www.bsped.org.uk/media/1798/bsped-dka-guideline-2020.pdf
Key diagnostic factors.
1st investigations to order.
Initial systolic blood pressure <90 mmhg, initial systolic blood pressure ≥90 mmhg, contributors, expert advisers, edward jude, md, mrcp.
Consultant Diabetologist and Endocrinologist
Tameside and Glossop Integrated Care NHS Foundation Trust
Honorary Professor, University of Manchester
Honorary Professor, Manchester Metropolitan University Manchester
EJ declares that he has no competing interests.
BMJ Best Practice would like to gratefully acknowledge the previous team of expert contributors, whose work has been retained in parts of the content:
Aidar R. Gosmanov, MD, PhD, FACE
Associate Professor of Medicine
Division of Endocrinology
Albany Medical College
Chief, Endocrinology Section
Albany VAMC
Laleh Razavi Nematollahi, MD
Assistant Professor of Medicine
Case Western Reserve University
ARG and LRN declare that they have no competing interests.
Gerry rayman, md, frcp.
Consultant Physician and Head of Service
Diabetes and Endocrine Centre and the Diabetes Research Unit
Ipswich Hospitals NHS Trust
GR has been paid for advisory board meetings with the following companies: Sanofi Aventis, Abbott Diabetes UK, Lilly Diabetes, and Bayer. GR has received lecture fees from Sanofi Aventis, Abbott Diabetes UK, Lilly Diabetes, Novo Nordisk, and Napp Pharmaceuticals Ltd.
Honorary Professor of Medicine
Norwich Medical School, University of East Anglia
Consultant Diabetes & Endocrinology
Norfolk and Norwich University Hospitals NHS Foundation Trust
KD is the chair of the Joint British Diabetes Societies for Inpatient Care. KD has received honoraria from Diabetes Professional Care to speak at its annual meeting about these guidelines. No other reimbursement has been received from commercial organisations with respect to these guidelines. KD has helped to develop educational materials on this subject for the European Association for the Study of Diabetes, but did not receive any reimbursement. For other work as the chair of JBDS, KD has received honoraria from Lilly for developing educational material.
Section Editor, BMJ Best Practice
AS declares that she has no competing interests.
Head of Research and Development, BMJ
LD declares that she has no competing interests.
Head of Editorial, BMJ Best Practice
AE declares that she has no competing interests.
Lead Section Editor, BMJ Best Practice
RW declares that she has no competing interests.
Comorbidities Editor, BMJ Best Practice
JC declares that she has no competing interests.
Drug Editor, BMJ Best Practice
AM declares that he has no competing interests.
Glasgow Coma Scale
Venepuncture and phlebotomy animated demonstration
How to perform an ECG animated demonstration
Diabetes type 2: should I take insulin?
Use of this content is subject to our disclaimer
Log in to access all of bmj best practice, help us improve bmj best practice.
Please complete all fields.
I have some feedback on:
We will respond to all feedback.
For any urgent enquiries please contact our customer services team who are ready to help with any problems.
Phone: +44 (0) 207 111 1105
Email: [email protected]
Your feedback has been submitted successfully.
An official website of the United States government
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .
Shriya sharma.
a Nepalese Army Institute of Health Sciences, Kathmandu, Nepal
Samikshya adhikari, sabin poudel, gaurab mainali, sumit kumar yadav.
b Shree Birendra Hospital, Kathmandu, Nepal
Introduction and importance.
Diabetic ketoacidosis (DKA) is considered to be a common presentation of type 1 diabetes mellitus in children. It occurs when absolute or relative insulin insufficiency prevents glucose from entering the cells for use as metabolic fuel, causing the liver to quickly break down fat into ketones for use as fuel source. As a result, ketones are overproduced, accumulating in the blood and urine making the blood acidic.
A 4 years and 8 months old child presented with the complaint of abdominal pain and vomiting along with polyurea, polydipsia and polyphagia. Routine examination of blood revealed that increased random blood glucose level. Once diagnosed, DKA was managed with fluid and insulin therapy with close monitoring and supervision.
DKA can be easily diagnosed. Proper management should be done on time to prevent complications like hypokalemia, hyponatremia leading to cerebral edema and shock.
Diabetic awareness programs and school educational tutorials are beneficial for community awareness of the signs and symptoms of diabetes.
Type 1 diabetes is due to autoimmune destruction of pancreatic beta cells which leads to insufficient insulin production resulting in hyperglycemia [ 1 ].The common symptoms presenting in type 1 diabetes are polyurea, polydipsia, and weight loss [ 2 ]. Severe fall in insulin levels leads to increase in lipolysis which will lead to increase in level of ketone bodies resulting metabolic acidosis and compensatory respiratory alkalosis [ 3 ]. Diabetes ketoacidosis (DKA) is the common presentation of type 1 diabetes mellitus in children. The prevalence of onset of diabetic ketoacidosis among type 1 diabetes mellitus was found to be 26.3% in one of the studies [ 4 ]. Common complications observed due to ketoacidosis are electrolyte abnormalities like hypokalemia, hyponatremia leading to cerebral edema and shock [ 5 ].
If Diabetic ketoacidosis is not treated on time, the compensatory mechanism will fail soon and lead to cerebral edema, mental confusion, unconsciousness, coma and death [ 3 , 6 ]. DKA is the most common cause of death in children and adolescents with type 1 diabetes and cause of half of all deaths in diabetic patients under the age of 24 years [ 7 ]. Immediate and aggressive intervention is required. Early medical management could prevent complications like cerebral edema, mental confusion, shock and death. Here, we present a successful medical management of a diabetic ketoacidosis as a first presentation in a child with type 1 Diabetes mellitus. This case has been reported accordingly in line with SCARE 2020 criteria [ 8 ].
A 4 years 8 months old school going male child presented to the Emergency department of Shree Birendra Hospital with complaints of abdominal pain in periumbilical region for 1 day. Pain was mild, acute on onset, non-radiating associated with irritability. He also had a history of multiple episodes of vomiting for the last 3 days. Vomitus was non-projectile consisting of partially digested food particles and water. It was non-bile stained, was not mixed with blood, and was non-foul smelling. He also had a history of polyuria, polydipsia, and polyphagia for 7 days. Day by day there was an increase in frequency of urine which was associated with increased water intake. There is a history of a 2 kgs weight loss within a week. He was born healthy at term following an uncomplicated pregnancy and was the second child of a non-consanguineous marriage. There was no any family history of type I DM and any chronic illness.
On physical examination, the child was irritable and dehydrated with a dry tongue and mucosa. Vitals recorded at the time of admission were as follows; blood pressure of 80/50 mmHg, pulse rate of 128 beats/min and were low volume, respiratory rate of 24 breaths/minute, oxygen saturation of 95% on room air, and body temperature were 98 °F. Systemic examinations were normal.
Routine examination of blood revealed an increase in random blood glucose level with value of 448 mg/dl (ref. 140 mg/dl) and hyponatremia with value of 130 mEq/L (ref. 136–145 mEq/L), however serum potassium, urea and creatinine levels were normal. Urine examination revealed that the urine was acidic, acetone positive and sugar was present in urine. Arterial blood gas analysis showed pH 7.23 (ref. 7.35–7.45), pCO 2 31 (ref. 35–45 mmHg), HCO 3 − 13.21 (ref. 22–26mmoL/l), and PO 2 102 (80–105 mmHg). Hematological examination was unremarkable.
Based on hyperglycemia, metabolic acidosis, and ketonuria a diagnosis of DKA was made and management was initiated. The child was shifted to Pediatrics intensive care unit (PICU) where he was given intravenous fluid of 320 ml normal saline IV over 1 hour at the rate of 20 ml/kg. Similarly, regular insulin 0.5 ml hourly at the rate of 0.05 unit/kg hr (1ml insulin in 23ml NS) and injection ceftriaxone 500 mg IV 12 hourly at the rate of 63 mg/kg/day were administered for the next 23 hours. The child was kept in N/2 IV Fluid 100 ml/hourly with 1mEq KCl in each 100 ml IV fluid. If random blood sugar fell below 250 mg/dl, N/2 IV fluid and 5% dextrose at 100ml/hourly with 1mEq KCl in each ml of 100 ml IV fluid was indicated. We kept our patient on nil per oral. Similarly, if random blood sugar falls below 200 mg/dl, N/2 IV fluid and 10% dextrose at 100 ml/hourly was indicated.
Further, the vitals were monitored hourly; random blood sugar and neurological assessment were done 2 hourly; renal function test, electrolyte were monitored 6 hourly. X-ray of chest to rule out pulmonary infections such as pneumonia, ultrasonography of abdomen to rule out any organ damage, ophthalmology consultations to rule out papilloedema were done. There were no significant findings on any one of them. After 5 days on PICU, our patient's symptoms gradually improved. He was started on an oral fluid and liquid diet. The random blood glucose levels monitored at different time intervals were in the normal range. We discharged the patient after 7 days of admission with advice of Insulin Glargine 6 units sc once a day and Insulin Lispro 4 units before breakfast, lunch and dinner. The patient was properly instructed to follow up after 1 week for insulin management as per glucose report.
DKA is life threatening complications of uncontrolled diabetes mellitus if proper intervention is not done on time [ 9 ]. Risk of developing DKA at manifestation of diabetes is high in young children (<2 years), girls, children of ethnic minority status, low socio-economic status [ [10] , [11] , [12] ]. Successful management of diabetic ketoacidosis depends upon swift diagnosis, regular monitoring of clinical and biochemical parameters with prompt intervention. The diagnosis of DKA can be made on the basis of biochemical criteria of random blood glucose level greater than 200mg/dl with a venous pH of level <7.3 and/or a bicarbonate (HCO3) level of <15 mmol/L; ketonemia and ketonuria [ 11 ]. Early detection of diabetic ketoacidosis in our case led to proper medical management of a patient preventing him from complications like cerebral edema. However, diagnosis of DKA should not be confused with asthma, hypokalemia, metabolic acidosis, respiratory acidosis, pneumonia, salicylate poisoning, acute abdomen, gastroenteritis etc. [ 13 ].
Muktan et al. in their retrospective study found that polyurea, polydipsia, weight loss, abdominal pain, vomiting as the most common symptoms of DKA [ 14 ]. Our patient also presented with similar symptoms from which we made a provisional diagnosis of DKA after physical examination which was later confirmed by biochemical examination. DKA can be managed in any hospital/private unit or in a pediatric inpatient ward in case of children by trained nursing and medical personnel.
Rosenbloom et al. in his study had described the management of Diabetic Ketoacidosis depends on the severity of DKA. The severity of DKA is categorized by acid-base status in which mild DKA has pH 7.2 to <7.3; bicarbonate 10 to <15 mEq/L, moderate DKA has pH 7.1 to <7.2; bicarbonate 5 to 9 mEq/L and severe DKA has pH < 7.1; bicarbonate <5 mEq/L [ 15 ]. Our patient had pH level of 7.23 and bicarbonate level at 13.21. Thus, he had a mild DKA and was treated accordingly.
The child presented with DKA should be closely monitored in the unit. Blood glucose, electrolyte level, neurological assessment, vitals, and urine routine examination should be monitored on hourly basis [ 16 ]. We monitored our patient's vitals hourly; random blood glucose level and neurological assessment 2 hourly; electrolyte, input/output charting, and urine routine examination 6 hourly.
The patient with DKA is treated with intravenous fluids and intravenous insulin if the child is nauseated/vomiting, clinically dehydrated or is not alert [ 17 ]. We managed our patient as per his symptoms. We used normal saline for the first 24 hours to treat and manage dehydration and mild sodium depletion. We kept our patient on Insulin to control increased random blood glucose level. KCL along with intravenous fluids was given to manage the impending hypokalemia. In order to treat and prevent possible bacterial infections, ceftriaxone was given. Since we kept our patient nil per oral, dextrose in intravenous fluids was introduced the next day.
We present a case of diabetic ketoacidosis in a child with type 1 diabetic mellitus. It is a life threatening complications if timely intervention is not done. Timely management with fluid therapy along with insulin should be done. Regular monitoring and neurological observation are equally important to prevent complications like cerebral edema. Educational programs, diabetes awareness campaigns, and school educational tutorials can be beneficial for community awareness of the signs and symptoms of diabetes.
We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.
We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.
We understand that the Corresponding Author is the sole contact for the Editorial process. He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.
This is a case report, therefore, it did not require ethical approval from the ethics committee.
Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the editor-in-chief of this journal on request.
Not applicable
The study did not receive any grant from funding agencies in the public, commercial or not-for-profit sectors.
All authors: writing the paper, collection of Data, revising it critically for important intellectual content, reviewing, and editing.
Shriya Sharma, Nepalese Army Institute of Health Sciences, Kathmandu, Nepal E-mail: [email protected]
Not commissioned, externally peer-reviewed.
The authors report no conflicts of interest.
Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2022.103981 .
The following is the Supplementary data to this article:
Watch More! Unlock the full videos with a FREE trial
Study tools.
Access More! View the full outline and transcript with a FREE trial
Mr. Logan is a 32-year-old male with a history of DM Type I. He presented to the Emergency Department (ED) after being found by his family with decreased LOC, rapid heavy breathing, and fruity breath. His family reports flu-like symptoms for the last few days.
Diabetic Ketoacidosis – he is a Type I Diabetic with heavy breathing (Kussmaul Respirations) and fruity breath. These are classic signs. It’s important to recognize them and immediately begin anticipating the patient’s needs.
The nurse draws a Complete Metabolic Panel and notifies the Respiratory Therapist to obtain an Arterial Blood Gas. Upon further assessment, the patient is oriented x 2 and drowsy. He is breathing heavily. Lungs are clear to auscultation, S1/S2 present, bowel sounds active, pulses present and palpable x 4 extremities. A POC glucose reads >450 (meter max).
Vital signs are as follows: HR 87 RR 32 BP 123/77 SpO 2 96%
Mr. Logan’s labs result and show the following: Glucose 804 mg/dL K 6.1 mEq/L BUN 39 mg/dL pH 7.12 Cr 1.9 mg/dL pCO 2 30 Anion Gap 29 mEq/L HCO 3 – 17 Urine = Positive for Ketones
The provider writes an order for an Insulin Lispro infusion IV, titrating to decrease blood glucose per protocol, 1L NS bolus NOW, and a continuous infusion of Normal Saline IV at 250 mL/hr, and to change the fluids to D5 ½ NS at 125 mL/hr once the blood glucose level falls below 250 mg/dL.
Remind the provider that the only insulin that can be given IV is Regular Insulin and request that he change the order. Call the Pharmacist if you have to
The provider adjusts the order to Regular Insulin IV infusion. Orders are also written for hourly POC glucose checks and a q2h BMP.
After 4 hours and another 1L bolus of NS, Mr. Logan’s blood glucose level has dropped to 174 mg/dL, but his anion gap is still 19. The nurse changes his fluids to D5 ½ NS per the order and continues the insulin infusion. The most recent BMP showed a K of 3.7, down from 6.1, so the provider orders to give 40 mEq of KCl PO.
After another 4 hours, Mr. Logan’s anion gap is now 12, a repeat ABG shows a pH of 7.36 with normal CO 2 and HCO 3 – levels. The nurse begins to transition Mr. Logan off of the IV infusion to SubQ insulin per protocol. He is feeling much better and says he’s embarrassed that he had to be brought to the hospital.
When you start a FREE trial you gain access to the full outline as well as:
“Would suggest to all nursing students . . . Guaranteed to ease the stress!”
This nursing case study course is designed to help nursing students build critical thinking. Each case study was written by experienced nurses with first hand knowledge of the “real-world” disease process. To help you increase your nursing clinical judgement (critical thinking), each unfolding nursing case study includes answers laid out by Blooms Taxonomy to help you see that you are progressing to clinical analysis.We encourage you to read the case study and really through the “critical thinking checks” as this is where the real learning occurs. If you get tripped up by a specific question, no worries, just dig into an associated lesson on the topic and reinforce your understanding. In the end, that is what nursing case studies are all about – growing in your clinical judgement.
Cardiac nursing case studies.
Respiratory nursing case studies.
Mental health nursing case studies.
Other nursing case studies.
Clinical pearls, case study: recurrent diabetic ketoacidosis resulting from spurious hypoglycemia: a deleterious consequence of inadequate detection of partial strip filling by a glucose monitoring system.
David A. Price, MD, FACE, is Executive Director of Clinical Affairs at LifeScan, Inc., in Milpitas, Calif.
Note of disclosure: Dr. Price is an employee of LifeScan, Inc., and holds stock in its parent company, Johnson and Johnson. LifeScan, Inc., manufactures and sells blood glucose monitoring systems for people with diabetes.
David A. Price; Case Study: Recurrent Diabetic Ketoacidosis Resulting From Spurious Hypoglycemia: A Deleterious Consequence of Inadequate Detection of Partial Strip Filling by a Glucose Monitoring System. Clin Diabetes 1 January 2009; 27 (4): 164–166. https://doi.org/10.2337/diaclin.27.4.164
Download citation file:
E.K., a 28-year-old woman with poorly controlled type 1 diabetes of 10 years' duration, presented with mild nausea, occasional vomiting, dizziness, and recurrent, asymptomatic severe hypoglycemia. In phone consultations with the physician's office in the preceding week, she had reduced her insulin in half because of recurrent, very low (usually asymptomatic) glucose readings but sporadic low glucose levels continued to be problematic. She also had episodic, marked hyperglycemia complicating her dosing decisions. Her patterns of high and low glucose appeared discordant with food intake and insulin dosing.
Her history was remarkable for diabetes and recurrent, intermittent nausea, vomiting, and diarrhea presumed to be manifestations of autonomic neuropathy. She had known hypoglycemia unawareness but had not had problems with unconscious hypoglycemia or seizures. She had no other known autoimmune disorders and no retinopathy or renal dysfunction.
She often missed office appointments and, until recently, had been erratic in her glucose monitoring. At the time of her presentation, she was on 10 units of NPH insulin in the morning and 5 units at night, with small doses of lispro only taken to compensate for very high glucose readings.
Her exam was remarkable for dry mucous membranes and orthostatic hypotension, with a sitting blood pressure of 98/74 mmHg and pulse of 102 bpm and a standing blood pressure of 72/40 mmHg and pulse of 120 bpm. Otherwise, she had normal skin pigmentation and no lipohypertrophy or lipoatrophy, and her neck, heart, lung, abdomen, and extremities were all unremarkable.
Because of the frequent low glucose levels, her insulin was further decreased, down to 7 units in the morning and 2 units at night, and she was provided new bottles of her insulins and test strips. She was instructed to aggressively hydrate and closely monitor her blood glucose and urine ketone levels. Fasting laboratory tests were obtained the next morning. Her A1C was 14%, thyroid-stimulating hormone was 1.84 with a free T4 of 1.5 ng/dl, fasting plasma glucose was 391 mg/dl, cortisol was 31.1 μg/dl (normal 8-24), adrenocorticotropic hormone was 53 pg/ml (normal 9-52), and kidney function, liver function, and anion gap were normal.
She developed increased ketonuria and had continued labile glucose levels and was admitted several days later with mild diabetic ketoacidosis (DKA). She was hydrated, and after parenteral insulin, her insulin dose was increased. Her meter glucose was compared to the lab on several occasions and correlated well.
She was considered stable enough to be discharged for close outpatient follow-up. However, her glucose levels remained chaotic, bouncing from > 400 mg/dl to a “Lo” reading on her meter. Few of the low glucose levels were symptomatic. In response to the profound hypoglycemia, insulin was repeatedly decreased.
Once again, she developed marked hyperglycemia and ketosis and had several emergency room visits for hydration. During each of these visits, her insulin was increased, but because of frequent low glucose readings, she would subsequently decrease her insulin dose. She continued to do poorly and lost weight from her baseline of 150 down to 135 lb.
With her inability to control her glucose levels and impending ketoacidosis, she was readmitted. During this hospitalization, she was instructed to self-monitor her blood glucose with her usual meter (Glucometer Elite, Bayer Diabetes Care, Tarrytown, N.Y.). Several times, her meter displayed “Lo” results that were inconsistent with the hospital meter system and the laboratory. In reviewing the labeling for E.K.'s meter, a diabetes nurse specialist noted that a “Lo” display could occur with incomplete strip filling (also called short or partial filling or short sampling). When her glucose monitoring technique was closely observed, it was discovered that she was visually filling the test strip using a minimal amount of blood. She was not waiting for the beep to confirm adequate strip filling as described in the meter's package instructions.
She was instructed on the proper use of her meter and was discharged. During the next several weeks, E.K. dramatically improved, gaining weight and stabilizing her insulin doses without further occurrences of unexplained hypoglycemia or ketoacidosis. She was then lost to follow-up.
What is the differential diagnosis of falling insulin requirements?
What are the causes of recurrent DKA?
What are the sources of error in self-monitoring of blood glucose (SMBG)?
What are the causes of short sampling?
In this case study, a patient had repeated, asymptomatic low glucose readings resulting in insulin dose reductions and culminating in repeated hospitalizations for DKA. After much detective work in which endocrine (adrenal, pituitary, and thyroid) and metabolic (renal, hepatic) derangements were ruled out, the low glucose readings were found to be the consequence of use error, failure to follow product labeling, and failure of the blood glucose meter to provide an error message with partial strip filling. Instead of an error message, “Lo” or low glucose readings were displayed on the glucose meter. Because both patients and health care professionals use glucose meter data to make treatment decisions, 1 , 2 it is imperative that either results are clinically accurate or an error message is provided if incomplete strip filling occurs.
Although the sample size requirement of many current blood glucose meters is small, short sampling can occur in numerous conditions, including states of vasoconstriction, use of small lancets and shallow lances, desire to minimize blood, and poor or rushed sampling technique. In a recent study by Grady et al., 3 200 subjects were asked to record their daily performance with SMBG using their current meter for 1 month. A simple questionnaire allowed each subject to record daily results from successful tests and to provide information about the reasons for any test failures. The main self-reported failure modes (573 failed tests out of 14,580 individual finger sticks) were “blood drop too small” (32.9%), “error on screen, (32.2%), “can't get blood in strip” (19.3%), and “did not trust the result” (15.5%). These results are evidence that significant problems may be encountered in blood sampling with current meters even by patients who have many years of SMBG experience.
Although current blood glucose meters are designed to detect and provide an error message if an inadequate blood sample is applied to the test strip, several published reports 4 - 7 suggest that inadequate sample application during blood glucose testing with some glucose meters could result in erroneously low glucose readings. The U.S. Food and Drug Administration 8 also recognizes that errors can be attributed to failure of glucose meters to detect an inadequate sample size. However, this is the first published report of deleterious health consequences attributed to this error.
There are several other potential sources of error with SMBG measurements that should be considered with unexplained high and low glucose readings. 2 , 3 , 9 These errors could be related to device factors, physiological factors, patient misuse of the meter, or medication interferences. 10 - 12 Each glucose meter has different enzymes, co-enzymes, mediators, electrode configurations, and manufacturing processes that lead to different characteristics, performance limitations, and interferences. The strip's enzyme activity can be affected by manufacturing variances, exposure to heat and humidity (such as improper storage of the strip outside a vial or failure to close a vial), and strip aging.
Physiological factors that may affect accuracy of some glucose meters include hematocrit extremes, oxygen extremes (for glucose oxidase-based systems) hyperuricemia, hypertriglyceridemia, and hyper-bilirubinemia. In addition, marked dehydration, vasoconstriction, or rapidly changing glucose levels may influence the accuracy of glucose measurement at some body sites.
Patient use errors may result in falsely elevated or decreased glucose measurements. Skin contamination from failure to wash hands is problematic. Misapplication of blood, including underdosing (as in this case), sample smearing, slow application, repeat blood application, or strip movement during application or throughout the test process may affect results. Miscoding meters diminishes the accuracy of the measurements. Incorrect unit of measure settings, date and time settings, or recordkeeping errors can affect glucose reporting and data interpretation.
Finally, medications (acetaminophen, L-dopa, tolazamide, and ascorbic acid) may interfere with some meters. When they occur, these interferences are often associated with levels of medication that significantly exceed physiological or desired levels. In some systems that use the enzyme GDH-PQQ, because it is not specific for glucose, falsely elevated glucose readings may occur in patients treated with agents that contain or are metabolized to maltose (i.e., icodextrin), galactose, or xylose. 13 The associated rise in “glucose” can be quite marked and has been associated with inappropriate insulin doses, severe hypoglycemia, and deaths.
Falling insulin requirements from recurrent hypoglycemia could occur with adrenal dysfunction, progressive renal insufficiency, hypothyroidism, placental insufficiency, changes in food intake or activity, surreptitious insulin administration, insulin errors, or glucose measurement errors. In the described case study, improper test strip filling and its lack of detection was determined to be the casual factor for spurious hypoglycemia, resulting in insulin dose reductions and culminating in repeated ketoacidosis.
Glucose monitoring errors should be considered when glucose results are inconsistent or do not fit the clinical situation. These errors can be related to device or physiological factors, patient misuse, or external interferences and may result in falsely high or low glucose readings.
It is important for patients and clinicians to understand the indications and limitations of the particular glucose meter they are using or recommending and should follow the labeled instructions for the device.
Routine evaluation of patients' SMBG technique is recommended. 14
Sign In or Create an Account
COMMENTS
Two patients with type 2 diabetes presented with diabetic ketoacidosis (DKA) and were found to have epidural and prostatic abscesses, respectively. The authors discuss the importance of considering alternative diagnoses and the risk factors for DKA in type 2 diabetes.
We presented a case of new-onset diabetes presenting as DKA precipitated by COVID-19 infection. The relationship between DKA and COVID-19 has been explored sparingly thus far in the literature. In a study by Li et al., that included 658 hospitalized patients with confirmed COVID-19 infection, 42 of them presented with ketosis on admission.
Use of this content is subject to our disclaimer. Diabetic ketoacidosis (DKA) is characterized by a biochemical triad of hyperglycemia, ketonemia, and acidemia, with rapid symptom onset. Common symptoms and signs include polyuria, polydipsia, polyphagia, weakness, weight loss, tachycardia, dry mucous membranes, poor skin turgor, hypotension, and...
Severe hypertriglyceridemia (HTG) is a rare complication of insulin resistance. Its presentation with diabetic ketoacidosis (DKA) has been reported in a few cases, where most patients have type-1 diabetes mellitus (DM). Our case represents a unique presentation of DKA associated with severe HTG above 10,000 mg/dL in an adult with type-2 DM.
Diabetic Ketoacidosis commonly presents with hyponatremia, but hypernatremia is a rare entity. We report a unique case of a 50-year-old woman admitted with altered sensorium with blood glucose 979 milligrams/deciliter, serum osmolarity 363 mOsm/kilograms, and serum sodium 144 milliequivalents/liter.
Diabetic ketoacidosis (DKA) is an acute complication of uncontrolled diabetes mellitus that is associated with increased morbidity and mortality. ... Original articles, consensus statements, professional guidelines, systematic and nonsystematic reviews, meta-analysis, case-control studies, cohort studies, case series and case reports published ...
Nurse Andrea works on a medical-surgical unit and is caring for Mario, a 32-year-old male with a history of type 1 diabetes mellitus, who was recently admitted from the emergency department for diabetic ketoacidosis, or DKA. After settling Mario in his room, Nurse Andrea goes through the steps of the Clinical Judgment Measurement Model to make ...
Diabetic Ketoacidosis Upon Diagnosis: A Biochemistry Case Study. Diabetes mellitus is a metabolic disorder characterised by hyperglycemia. The two main types of diabetes mellitus are type 1 diabetes mellitus (T1DM) and type 2 (T2DM), which exhibit similar symptoms while having two very difer-ent pathophysiologies (Alam et al., 2014).
A case of misdiagnosed type 1 diabetes presenting with euglycemic diabetic ketoacidosis (EDKA) while taking empagliflozin and following a ketogenic diet. The article discusses the mechanisms, risks, and management of EDKA in patients with type 1 diabetes and SGLT2 inhibitors.
Background Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes that requires immediate treatment. Allergic reaction to insulin is rare, especially when using recombinant human insulin. The clinical presentation of insulin allergy can range from minor local symptoms to a severe generalized allergic reaction such as anaphylaxis. A limited number of cases ...
On March 6th, 2019, Maria Fernandez, a 19-year-old female, presented to the Emergency Department with complaints of nausea, vomiting, abdominal pain, and lethargy. She reveals a recent diagnosis of type 1 diabetes but admits to noncompliance with treatment. At the time of admission, Maria's vital signs were as follows: BP 87/50, HR 118, RR 28 ...
Diabetic ketoacidosis (DKA) is characterised by a biochemical triad of hyperglycaemia (or a history of diabetes), ketonaemia, and metabolic acidosis, with rapid symptom onset.Common symptoms and signs include increased thirst, polyuria, weight loss, excessive tiredness, nausea, vomiting, dehydration.
A 30-year-old man with type 2 diabetes developed diabetic ketoacidosis after starting a low-carbohydrate ketogenic diet. He was misdiagnosed with type 2 diabetes and later found to have type 1 diabetes or latent autoimmune diabetes in adults.
Diabetic ketoacidosis (DKA) is a serious complication of diabetes mellitus caused by insulin deficiency and hyperglycemia. Learn about the pathophysiology, diagnosis, treatment, and prevention of ...
Diabetic ketoacidosis, or DKA for short, is a life-threatening complication of diabetes mellitus characterized by a severe insulin deficiency and glucagon excess. It typically but not exclusively occurs in the setting of type 1 diabetes, with common triggers that include illness or infection, as well as known diabetes with suboptimal glycemic ...
Abstract. Diabetic ketoacidosis (DKA) is an acute complication of diabetes mellitus, both type I and type II, as well as other types with diabetes such gestacional diabetes mellitus. It is characterized by blood glucose levels greater than 250 mg/dL and metabolic acidosis (pH < 7.3 and serum bicarbonate < 15 mEq/dL) with an increased anion gap ...
Learn how to recognize and manage a child with diabetic ketoacidosis (DKA) in this online simulation case. Follow the steps of history, exam, labs, fluids, insulin, potassium and communication with caregivers and consultants.
Diabetic ketoacidosis - a diagnosis not to be missed JOHN N HARVEY AND JOHN W GREGORY Diabetic ketoacidosis (DKA) is the leading cause of death before the age of 30 in people with type 1 diabetes, therefore prompt diagnosis and treatment is vital. This article provides some clinical case studies to illustrate how the presentation of DKA can
** The data in Tables 1 and 2 (following page) and the description of the patient's condition and treatment have been modified from a case reported by A.N. Cebeci and A. G. Üven ("Delirium in Diabetic Ketoacidosis: A Case Report," The Journal of Clinical Research in Pediatric Endo-crinology . 4(1): 39-41, 2012).
A case report of a patient with type 2 diabetes who developed euglycemic diabetic ketoacidosis (DKA) while taking sitagliptin and empagliflozin and following a ketogenic diet. The article discusses the possible mechanisms, precipitating factors, and management of this rare complication of SGLT2 inhibitors.
Diabetic ketoacidosis (DKA) is characterised by a biochemical triad of hyperglycaemia (or a history of diabetes), ketonaemia, and metabolic acidosis, with rapid symptom onset. ... Case Western Reserve University. Cleveland. OH. ... KD has helped to develop educational materials on this subject for the European Association for the Study of ...
The prevalence of onset of diabetic ketoacidosis among type 1 diabetes mellitus was found to be 26.3% in one of the studies . ... We present a case of diabetic ketoacidosis in a child with type 1 diabetic mellitus. It is a life threatening complications if timely intervention is not done. Timely management with fluid therapy along with insulin ...
The #1 priority for DKA is to get the blood sugar down and get insulin into the system. Getting insulin into the system allows the gluconeogenesis to STOP (so that the body will STOP making ketoacids and start using the glucose it has). The #2 priority is fluid replacement due to severe dehydration from osmotic diuresis.
David A. Price; Case Study: Recurrent Diabetic Ketoacidosis Resulting From Spurious Hypoglycemia: A Deleterious Consequence of Inadequate Detection of Partial Strip Filling by a Glucose Monitoring System. ... In the described case study, improper test strip filling and its lack of detection was determined to be the casual factor for spurious ...